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ABSTRACT 
 
Since the discovery of pyrrolysine as the 22nd amino acid, the field of chemical 
biology has expanded tremendously with important developments made in genetic 
noncanonical amino acid (ncAA) incorporation based on the pyrrolysine incorporation 
machinery. As first discovered in methanogenic archaea, pyrrolysine is incorporated using 
pyrrolysyl-tRNA and the cognate pyrrolysyl-tRNA synthetase which install this amino 
acid using an in-frame stop codon present on the mRNA. This archaeal synthetase and 
tRNA form an orthogonal pair in naïve organisms such as Escherichia coli, mammalian 
cells etc. and have been engineered over the past few years to incorporate several different 
noncanonical amino acids in proteins genetically. Although this system serves as an 
important chemical biology tool, it leaves much to be desired in terms of incorporation 
efficiency of these different unnatural amino acids.  
In this dissertation, we have explored the method for optimizing this remarkable 
system to achieve high levels of ncAA incorporation by engineering its N-terminal 
domain. Further, we then examined its application in improving other tRNA/synthetase 
systems which have been created for incorporation of specific ncAAs by researchers in 
previous years. In addition, we have also probed the feasibility of incorporating several 
histidine derivatives in proteins in using an engineered C-terminal domain version of this 
synthetase and the cognate tRNA to be able to study mechanism of enzymes employing 
histidines in their catalytic activity. In particular, the mechanism of alanine racemase 
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enzyme was probed to validate the existence of a proton transfer chain near the catalytic 
site of the enzyme crucial to its activity.  
Overall, our results can be translated to other orthogonal tRNA/synthetase pairs 
derived from pyrrolysyl-tRNA/synthetase to achieve improvement in existing ncAA 
incorporation systems and hence resolve the poor incorporation problem of these ncAAs. 
Also, the system developed by us can be used to probe several enzymes which employ 
histidine triads in their catalytic mechanism. It can also be used to modify or fine-tune the 
activity of these enzymes without compromising protein structure.   
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PCR Polymerase Chain Reaction 
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PTM Post-translational modification 
PylRS Pyrrolysyl-tRNA synthetase 
PylT Pyrrolysyl-tRNA 
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SAM S-Adenosyl methionine 
SDS Sodium dodecyl sulphate 
sfGFP Super-folder green fluorescence protein 
SPPS Solid-phase peptide synthesis 
SUMO Small ubiquitin-related modifier 
Ta Thiazolyl alanine 
TEV Tobacco etch virus 
TFA Trifluoroacetic acid 
THF Tetrahydrofuran 
tRNA Transfer ribonucleic acid 
Tyr or Y Tyrosine 
WT Wild-type 
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CHAPTER I  
INTRODUCTION AND LITERATURE REVIEW 
 
Protein Biosynthesis 
As outlined by the central dogma of microbiology, genetic information gets 
transferred from DNA to RNA via a process known as transcription and from RNA to 
protein by a process known as translation.[1] This process of protein biosynthesis in living 
organisms usually involves 20 naturally occurring (canonical) amino acids and occurs on 
the ribosome. After the messenger RNA (mRNA) strand is transcribed from DNA, this 
mRNA is read by the ribosome and decoded based on its triplet nucleotide sequence, also 
known as codons (Figure I-1). As the first step of the protein synthesis, known as 
activation, transfer RNAs (tRNAs) are charged with the corresponding amino acid by their 
cognate aminoacyl-tRNA synthetases. The next step, also known as initiation, involves 
the smaller ribosomal subunit binding to the 5’ end of the mRNA strand with the use of 
initiation factors (IFs).[2] Following initiation, elongation occurs as the next step in the 
process where elongation factors (EFs) assist in delivering charged tRNAs to the A-site of 
the ribosome. Peptidyl transferase activity ensues next, and the growing peptide chain is 
moved to the P-site of the ribosome along with movement of the ribosome towards the 3’ 
end of the mRNA by the length of a codon. The uncharged tRNA is then released through 
the E-site of the ribosome. This entire process repeats itself until the ribosome reads one 
of the stop codons (UAA, UAG and UGA) which results in termination of the protein 
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synthesis.  This final termination step utilizes release factors (RFs) to disassemble the 
protein translational machinery.  
 
 
 
 
 
 
 
  
Figure I-1. The standard genetic code 
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Post-Translational Modifications 
After the completion of the translation process, the synthesized proteins undergo 
various covalent modifications known as post-translational modifications (PTMs) to 
achieve their complete biological functionality.[3] There are more than 87,000 
experimentally identified post-translational modifications so far and they broadly fall in 
one of the following PTMs, phosphorylation, methylation, glycosylation, acylation, 
ubiquitylation, citrullination, S-nitrosylation, hydroxylation, etc. (Figure I-2).[4-6] 
All these PTMs serve diverse roles in altering the property, structure and function 
of proteins. Modifications such as phosphorylation, methylation and acetylation tweak the 
charged state of protein and play important roles in regulation of several cellular processes 
such as cell growth, intracellular signal transduction, apoptosis, etc.[5, 7-10] Glycosylation 
on the other hand changes protein’s conformation and stability and regulates intercellular 
signaling pathway.[11] Acylation modifications such as palmitoylation and GlcNAcylation 
affect interaction of proteins with lipids and membranes and hence control protein 
trafficking, aggregation and stability.[12, 13] The ubiquitylation modification affixes 
polyubiquitin chains on proteins thereby marking them for degradation.[14] Apart from 
these few examples mentioned above, the other PTMs also serve important roles in 
regulating various cellular functions and misregulation of these PTMs is the cause of 
various diseases.[15] 
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Figure I-2. A few common post-translational modifications. 
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The important roles played by these post-translationally modified proteins in 
maintaining normal cellular functioning of living organisms proves that nature requires 
more than the 20 naturally occurring amino acids to manage proper order for life.  These 
observations resulted in a need to build a suitable method to experimentally install these 
PTMs in proteins in the form of noncanonical amino acids (ncAAs) to be able to study the 
structure and functions of these biological molecules in detail. 
 
Histone Post-Translational Modifications 
It is especially important to mention post-translational modifications in context of 
histone proteins. Histone proteins are evolutionarily conserved and are responsible for 
efficient packaging of genetic material in cells in form of chromatin. Chromatin fiber is a 
polymer consisting of repeating units of nucleosomes, where each nucleosome is 
composed of 146 base pairs of DNA wrapped around a histone octamer of two histone 
H2A, H2B heterodimers and a histone H3, H4 tetramer, linked together by H1 histone 
protein (Figure I-3).[16, 17]  
The N-terminal tails of these histone proteins undergo several covalent post-
translational modifications, such as acetylation, methylation, phosphorylation, 
ubiquitylation, sumoylation, ribosylation, etc. as mentioned in the section above, which 
dynamically regulate each other by a process termed as histone ‘cross-talk’.[18] These 
modifications on histones are responsible for modulating several important cellular 
processes such as gene transcription, DNA repair, replication, etc. and form epigenetic 
markers.[18-20] Aberrant cross-talk results in detrimental overexpression of genes or 
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repression of essential genes and the resulting dysregulation of several of these PTMs have 
been implicated in diseases such as diabetes, cancer, Alzheimer’s disease, etc. as the 
mechanism regulating the cell repair and expression/repression of various important genes 
is impaired in these diseases.[21, 22]  
Among all these post-translational modifications, histone acetylation has been one 
of the most well studied PTMs. Several key lysine residues on all four histone proteins 
(H2A, H2B, H3 and H4) have been identified which undergo acetylation, and the 
modification is known to regulate transcriptional activation, DNA damage repair and 
chromatin assembly.[23] Since acetylation leads to neutralization of charge on the protein 
tail, it is assumed that this leads to loosening of the DNA-protein complex by reducing the 
electrostatic interactions between DNA and histone and leads to a ‘euchromatin’ state, the 
transcriptionally active state of chromatin (Figure I-3). In this form the DNA is accessible 
to transcriptional machinery, hence acetylation of N-terminal tail of histone regulates 
chromatin remodeling and controls gene transcription. Conversely, histone methylation 
results in a ‘heterochromatin’ state in which transcriptional machinery is inactive due to 
condensed chromatin form (Figure I-3). Methylation usually occurs on arginine & lysine 
residues of the histone tail. Methylation, along with acetylation, is known to regulate 
expression of various genes, overexpression of several of which results in a diseased cell 
state. Thus, all these PTMs form a transcription regulation code, often referred to as the 
‘histone code’.[24] 
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Figure I-3. Regulation of chromatin structure and gene transcription. 
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Other histone PTMs such as phosphorylation, ADP-ribosylation, ubiquitylation 
and SUMOylation along with acetylation and methylation form intricate cross-talk maps. 
So far, studies have shown histone H3S10 phosphorylation, which is a transcription 
activating mark, affects acetylation on the same histone tail (cis crosstalk) at histone H3K9 
& H3K14, inhibiting one and promoting the other.[25] More recently, phosphorylation at 
H3S10 has been shown to trigger H4K16 acetylation (trans crosstalk) leading to 
transcription activation.[26] These and several other discovered cross-talks[27-30] (Figure I-
4) have piqued interest of researchers all over the world to explore this field further due to 
their significant biological implications. 
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Figure I-4. Map showing some of the cross-talk interactions between different histones. 
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The development of efficient methodology to detect & map these cross-talks on a 
single nucleosome, and the importance of knowing the cross regulatory mechanism of 
these modifications has motivated us in trying to resolve several unanswered questions 
related to cross-talks. The following section discusses the known methods for obtaining 
post-translationally modified nucleosomes and proteins in general. 
 
Noncanonical Amino Acid Incorporation 
As mentioned above, suitable methodology is required for incorporation of ncAAs 
in proteins to be able to manipulate their chemical properties such as stability, structure 
and function and to be able to reconstitute nucleosomes with PTMs. The earliest methods 
devised involved chemical approaches to obtain these results. Techniques such as solid-
phase peptide synthesis (SPPS)[31], native chemical ligation (NCL)[32, 33] and expressed 
protein ligation (EPL)[34] were used to chemically install non-native amino acids in 
peptides and proteins synthesized in vitro.  
 
Synthetic Techniques 
Pioneered by Bruce Merrifield, solid phase peptide synthesis (SPPS) technique 
was developed in 1963.[35] The general scheme of SPPS involves using a polystyrene resin 
as solid support which is modified by a linker to which the C-terminal of the first amino 
acid can be attached by use of activators (Figure I-5).[36] The amino acid so attached is 
protected on the N-terminal group by tert-butoxycarbonyl (Boc) group which is sensitive 
to trifluoroacetic acid (TFA) deprotection or fluoren-9-ylmethyloxycarbonyl (Fmoc) 
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group which is sensitive to deprotection in basic conditions.[37] Followed by peptide 
coupling and deprotection, this strategy can yield peptides and proteins less than 100 
residues in length and has been one of the earliest methods used for incorporation of 
ncAAs. The main disadvantages of this technique lie in the limitation posed on the length 
of the peptide that can be synthesized, chemical groups that can be introduced in the form 
of non-canonical amino acid and cost ineffectiveness.[38]  
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Figure I-5. General scheme of solid phase peptide synthesis. 
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To overcome the constraint on the length of the peptide that can be synthesized, a 
technique called as native chemical ligation (NCL) was devised in 1994.[39] This highly 
chemoselective strategy requires an N-terminal cysteine residue present on a peptide 
which spontaneously reacts with another peptide with α-thioester on its C-terminal, when 
mixed in mild denaturing conditions at neutral pH by formation of thioester linkage which 
rearranges in an intramolecular fashion to yield native peptide bond (Figure I-6). This 
reaction does not require protection of side chains or additional cysteine groups as only 
the N-terminal cysteine residues take part in such a reaction.[40]  
This method has been used for synthesis of peptides containing ncAA longer than 
100 residues in length. It is especially appealing to utilize this technique when synthesizing 
peptides incorporating ncAAs that can be toxic to cells.[41] Although elegant, this 
technique is performed in organic solvent such as dimethylformamide (DMF) which 
causes the protein to mis-fold, rendering the synthesized protein less useful for 
applications requiring native protein. Other disadvantages such as low yield of peptide 
obtained, inefficiency for synthesis of complex and longer proteins and being highly labor 
intensive render this technique unattractive.[42]   
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Figure I-6. General strategy of native chemical ligation. 
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Semi-synthetic Technique 
A semi-synthetic technique known as expressed protein ligation (EPL) was 
devised next which combined native chemical ligation strategy with a protein expressed 
recombinantly.[43] The expressed protein generates an α-thioester as an intermediate on its 
C-terminal by protein splicing of mutant intein.[42, 43] The α-thioester generated then reacts 
with a peptide containing N-terminal cysteine to afford a semisynthetic product (Figure I-
7). 
This technique has been used for incorporation of several ncAAs at different sites 
in proteins to generate peptide/protein much longer than 100 residues in length.[44-46] 
However, like other chemical synthetic strategies, it requires presence of special chemical 
functionalities to be present for subsequent chemoselective reaction to take place and 
hence poses several restrictions on its application. The poor yield of product obtained 
using this strategy also makes it a cumbersome and expensive strategy to utilize for 
generation of ncAA incorporated protein. 
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Figure I-7. Expressed protein ligation strategy. 
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Although, all these techniques pioneered progress in the field of ncAA 
incorporation, there are several limitations to these techniques. Drawbacks such as 
constraint on the position where modification is possible, length of the peptide chain that 
can be synthesized and design constraints render these techniques inefficient.[33, 47]  
Another disadvantage of these techniques is their inapplicability for in vivo protein and 
enzyme studies due to mis-folding of protein obtained using these methodologies. 
 
Biosynthetic Techniques 
Other biosynthetic in vitro techniques have been developed to incorporate ncAAs 
by use of protein synthesis machinery existing in nature. These techniques are based on 
adaptor hypothesis,[48] as per which the interaction between a mRNA codon and the anti-
codon of tRNA is not dependent on the amino acid attached to the 3’ terminal of the 
aminoacyl charged tRNA and therefore an aminoacyl tRNA (x-tRNAx) can be charged 
with an ncAA (y-tRNAx) to incorporate it into a peptide in vitro.[49, 50] The major drawback 
of this technique is non-site-specific incorporation of the desired ncAA in proteins as it 
gets installed throughout the protein sequence at the sites corresponding to the specific 
codon.[51] Also, this technique yields misincorporated protein as the ncAA is in 
competition with the canonical amino acid, resulting in the latter being incorporated too 
at a few of the corresponding codon sites.[52] Another drawback of this method is the 
limitation on the ncAAs that can be incorporated using this system based on their chemical 
reactivity and interaction with tRNAs as the tRNA cannot by enzymatically mischarged 
due to its high specificity and chemically mischarging the tRNA poses a challenge due to 
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several reactive sites on the tRNA.[53] Other disadvantages include high expense and low 
yield of protein obtained using this technique as it can usually be employed only on a 
small scale. 
The next major advancement in this field occurred in 1989 with the development 
of a semisynthetic general technique for site-specific incorporation of ncAA by Noren et 
al.[54] This technique utilized UAG, a stop codon, to code for the desired ncAA instead of 
its usual function of terminating the polypeptide synthesis in the natural protein synthesis 
machinery. Since UAG is the most rarely used stop codon out of the three stop codons, 
namely amber, opal and ochre stop codons (UAG, UGA and UAA), it is seldom utilized 
in termination of essential genes in organisms. Based on this knowledge, the desired site 
for ncAA incorporation is mutated to TAG using site-directed mutagenesis technique and 
a chemically modified amino-acylated suppressor tRNA, directed specifically against 
UAG codon, is supplied to this system to get site-specific ncAA incorporation.[54, 55]  
As mentioned by the authors, [54] the other scientific observations that contributed 
to the development of this technique are as follows: 1) Development of functionally 
efficient amber suppressor tRNAs,[56] 2) Experimental evidence of adaptor hypothesis as 
mentioned previously, according to which the interaction between mRNA codon & anti-
codon region of tRNA is independent of the amino acid attached to the 3’ terminus of the 
aminoacylated tRNA,[49, 57] 3) Broad substrate specificity demonstrated by 
peptidyltransferases and elongation factors, indicating that ribosomes can accommodate 
an array of different amino acids with modified side chains, 4) Chemical synthesis 
approach developed to obtain tRNAs aminoacylated with amino acids lacking free amino 
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group (N-protected amino acids) which could only be accommodated at the P-site of 
ribosome[58, 59] and 5) the subsequent development of strategy to synthesize tRNAs 
aminoacylated with N-deprotected amino acid derivatives, so that they could be 
accommodated at the A-site of the ribosome as well, thus overcoming the challenge of 
chemically mischarging tRNAs.[60]  
 
In Vivo Incorporation Technique 
The successful in vitro implementation of this technique prompted progress in 
development of strategy to achieve in vivo incorporation of ncAA by extending the 
approach used in this methodology. Earlier in vivo techniques involved the use of 
auxotrophic strains to incorporate ncAAs but possessed several disadvantages such as 
requirement of the ncAA being incorporated to be a close structural homolog of the 
canonical amino acids and limitations on applicability of this method due to the toxicity 
of the ncAA being incorporated to the biological system and misincorporation of the 
homolog canonical amino acid by this system.[61]  
It was recognized that for efficient in vivo incorporation of ncAAs, the amino acid 
being incorporated requires to be soluble, stable and transportable across the cellular 
membrane. Apart from these specification requirements for the ncAA, a system would be 
required with an orthogonal tRNA and corresponding tRNA synthetase which utilize a 
nonsense codon to encode the ncAA. Orthogonality implies that this tRNA is not 
aminoacylated by any of the 20-canonical aminoacyl tRNA synthetases and 
correspondingly the orthogonal tRNA synthetase does not charge any of the 20-canonical 
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aminoacyl tRNAs. This is to ensure that the ncAA charged tRNA avoids detection by the 
cellular proofreading system which prevents misacylation of the tRNAs.[62]  It was 
discerned that orthogonality could be achieved by utilizing tRNA/synthetase pair from a 
different organism, granted the inefficiency of cross-species aminoacylation.  
The first successful implementation of such a system employed tyrosyl-
tRNA/synthetase pair from archaea Methanococcus jannaschii for ncAA incorporation in 
E. coli.[63] This tRNA/synthetase pair was chosen since it does not recognize endogenous 
tyrosyl-tRNA /synthetase of E. coli due to the differences in recognition elements between 
them.[64] The tRNA acceptor stem plays a prominent role in recognition of the tRNA by 
the synthetase and the acceptor stems of M. jannaschii tRNATyr differs from that of E. coli 
tRNATyr. The first base pairs on the acceptor stem of M. jannaschii tRNATyr are C1:G72, 
whereas in E. coli the first base pairs are G1:C72, hence they are orthogonal to each other. 
Also, the M. jannaschii tRNA synthetase lacks a proofreading mechanism, which implies 
that it does not edit out the non-canonical amino acid attached on the 3’ terminus of the 
tRNA.[65] It has also been shown that tRNACUA
Tyr
, which is the tRNAtyr with modified 
anticodon region, is not recognized by other E. coli synthetases but serves well in the E. 
coli protein translation machinery.[63, 64] This system has been evolved and utilized to 
incorporate several different ncAAs since its first application.[42] 
Although great ncAA substrate diversity was achieved by engineering and 
evolving this M. jannaschii tRNA/synthetase pair, due to constraints posed by amino acids 
that can be accommodated at the catalytic domain of this tRNA synthetase, this system 
also has its limitations. Hence, other possible orthogonal tRNA/synthetase pairs were also 
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explored to increase the chemical diversity of amino acids that can be incorporated using 
similar design. Several orthogonal pairs were utilized to this end including aspartyl-
tRNA/synthetase, tyrosyl-tRNA/synthetase, glutaminyl-tRNA/synthetase pairs from 
Saccharomyces cerevisiae.[66-68]  
The next development occurred after the discovery of 22nd genetically encoded 
amino acid, pyrrolysine,[69, 70] which paved the way for utilization of pyrrolysyl-
tRNA/synthetase pair for ncAA incorporation. This system was used in all the studies 
mentioned later and is explained in detail below. 
 
Pyrrolysine Biosynthesis and Incorporation 
After the discovery of selenocysteine as the 21st genetically encoded amino acid in 
1986,[71] pyrrolysine was identified as the 22nd amino acid almost two decades later in 
2002.[69, 70] These two amino acids are unique in the sense that they are naturally encoded 
by nonsense codons UGA and UAG respectively, however the mechanism of their 
encoding is vastly different from each other. Out of these two, mechanism of encoding 
pyrrolysine is of great interest since it is encoded by an in-frame amber stop codon (UAG) 
and has become an important chemical biology tool for ncAA incorporation.  
As first observed in the archaeal Methanosarcinaceae family, pyrrolysine is 
biosynthesized from two molecules of lysine in the natural pathway. The gene products of 
pylBCD gene, namely PylB, PylC and PylD, implement the biosynthesis process as 
illustrated in Figure I-8.[72] The product PylB (radical SAM enzyme) converts one of the 
lysine molecules into a methylated D-ornithine derivative which then ligates to the other 
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lysine residue in a reaction catalyzed by PylC (member of carbomyl phosphate synthetase 
family). PylD (contains NAD-binding domain) then catalyzes the oxidation of the 
resultant dipeptide formed, leading to elimination of water and formation of pyrrolysine 
as the final product.[73, 74] The remaining pyl genes, pylT and pylS  produce pyrrolysyl 
tRNA (tRNAPyl) and pyrrolysyl-tRNA synthetase (PylRS) as the gene products. The 
PylRS aminoacylates the tRNAPyl with pyrrolysine which subsequently encodes this 
amino acid in the in-frame UAG codon present in MtmB, MtbB and MttB, which are the 
pyrrolysine containing proteins responsible for metabolism of monomethylamine, 
dimethylamine and trimethylamine respectively in the methanogens to generate 
methane.[75-77] Apart from methanogenic archaea, pyrrolysine and hence pyl genes are also 
found in certain bacteria, namely Desulfitobacterium hafniense and deltaproteobacteria 
found in Olavius algarvensis worm.[78, 79] 
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Figure I-8. Pyrrolysine biosynthesis pathway. 
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This archaeal pyrrolysyl-tRNA/synthetase pair was thus recognized as potential 
orthogonal pair for efficient incorporation of ncAAs in E. coli[80] and efforts were then 
directed in engineering this system to achieve substrate diversity of ncAA that can be 
recognized by the PylRS. In recent years, engineered tRNAPyl/ PylRS from 
Methanosarcina barkeri and Methanosarcina mazei have become dominantly used 
orthogonal incorporation pairs for genetic incorporation of ncAAs in E. coli.[81]  
 
Pyrrolysyl-tRNA Synthetase Structure 
The structure of pyrrolysyl-tRNA synthetase has been studied in detail since 
pyrrolysine was discovered as the 22nd amino acid in order to determine strategies for 
engineering the synthetase for modifying its ncAA substrate recognition ability.  
PylRS is a homodimer and is encoded by pylS gene in archaea with each monomer 
consisting of a distinct catalytic C-terminal domain and an N-terminal domain.[82] In 
bacteria, the PylRS is encoded by two different genes pylSc and pylSn which encode the 
C-terminal and the N-terminal domain of the synthetase respectively.[83] This tRNA 
synthetase belongs to class II of aminoacyl-tRNA synthetases as determined by the 
structural details of its ATP-binding domain.[82] Its catalytic domain consists of 
antiparallel β-sheets surrounded by α-helices which are typical characteristics of class II 
aminoacyl-tRNA synthetases.[84]  
The crystal structures of C-terminal domains of Methanosarcina mazei PylRS and 
Desulfitobacterium hafniense PylRS have been resolved using X-ray crystallography and 
provide insight into substrate recognition elements of its catalytic domain (Figure I-9).[82, 
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83, 85, 86] Hydrophobic interactions between the substrate and the PylRS determine the 
affinity of the synthetase for the substrate and the specificity of the substrate is determined 
by the hydrogen bonding interactions between the active site of the synthetase and the 
substrate.[82] Based on this knowledge it was predicted that the potential substrates for the 
synthetase should contain certain key structural elements such as the carboxylate group 
should be separated from the α-amino group by six atoms.[87] Since canonical amino acids 
lack this structural element, the pyrrolysyl-tRNA/synthetase pair acts as an excellent 
orthogonal pair. Also, it was determined that lysine derivatives act as suitable substrates 
for the wild-type synthetase without the need of much engineering of the active site, since 
the synthetase can tolerate alterations and substitutions to the pyrroline side chain of the 
substrate as long as the lysine derivatives have a bulky hydrophobic group that can be 
accommodated in the active site in place of pyrroline ring.[82, 88] 
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Figure I-9. A. Catalytic (C-terminal) domain of Methanosarcina mazei PylRS 
(PDB:2E3C). B. Catalytic (C-terminal) domain of Desulfitobacterium hafniense 
PylRS (PDB:2ZNJ) 
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As mentioned earlier, the substrate specificity is determined by the hydrophobic 
and hydrogen bonding interactions between the substrate and the active site of the 
synthetase. One of the key residues at the active site of the synthetase is Y384 present on 
the mobile loop, which plays an important role in orienting the substrate at the catalytic 
domain through hydrogen bonding interactions between its -OH group and the nitrogen 
atoms on the pyrrole ring and the α-amino group.[82, 89] The Y384 residue also greatly 
stabilizes the complex formed between the substrate and the active site of the synthetase 
through van der Waals interaction energy gained between substrate and itself. Another 
important residue determining the substrate specificity is N346 residue which forms an 
indirect hydrogen bond with the α-amino group of the pyrrolysine through water and a 
direct hydrogen bond with the carbonyl oxygen.[82] The hydrogen bonding interaction 
between R330 and the carbonyl group also helps in the proper orientation of the 
substrate.[82, 86] The C348 residue at the active site of the synthetase has also been shown 
to interact with the carbonyl group of the substrate in place of N346 residue in case of 
certain ncAAs.[90] 
Based on the structural and functional knowledge of the key residues of the 
catalytic domain of the PylRS, the active site of Methanosarcina barkeri and 
Methanosarcina mazei PylRS have been modified by several researchers over the last 
decade for increasing the suitable ncAA substrate range that can be recognized by the 
synthetase and include several lysine and phenylalanine derivatives.[91] This dissertation 
explores the ability to  further expand the suitable substrates that can be incorporated by 
this orthogonal pyrrolysyl-tRNA/synthetase system to several histidine derivatives as 
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mentioned in chapter III.  The engineered pyrrolysine-tRNA/ synthetase system used for 
studies mentioned in the following chapters is based on the pyrrolysine incorporation 
machinery as illustrated in Figure I-10. 
 
 
 
 
 
 
 
  
Figure I-10. Pyrrolysine machinery used for ncAA incorporation. 
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Although, so much is known about the catalytic C-terminal domain of the archaeal 
and bacterial pyrrolysyl-tRNA synthetase, the function of N-terminal domain of the 
synthetase remains relatively unexplored. This is due to the inability in crystallizing the 
N-terminal domain caused by its insolubility. Recent studies have shown that the N-
terminal domain of the PylRS plays an important role in binding the tRNAPyl.[92] This 
dissertation explores effect of engineering this N-terminal domain on overall incorporation 
efficiency of the system as detailed in chapter II.  
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CHAPTER II  
ENGINEERING THE N-TERMINAL DOMAIN OF PYRROLYSYL-TRNA 
SYNTHETASE 
 
 
Introduction 
The last two decades have seen tremendous growth and interest in the field of site-
specific genetic incorporation of non-canonical amino acids (ncAAs) due to the 
applicability of this method to modify the structural and functional properties of various 
enzymes and proteins by altering the desired amino acid at the sites of interest.[93] The 
genetic ncAA incorporation system, as illustrated in Figure I-10, utilizes a rare codon 
suppression system, usually amber (TAG) codon and consists of an orthogonal tRNA and 
corresponding tRNA synthetase that can incorporate the required ncAA at the amber 
mutation site in the protein of interest.[94] For expression in the bacterial Escherichia coli 
system, orthogonality is achieved by utilizing the amber suppressor tRNA/synthetase pairs 
from archaea such as pyrrolysyl-tRNA/synthetase from Methanocaldococcus jannaschii, 
Methanosarcina barkeri, or Methanosarcina mazei, or the tyrosyl-tRNA/synthetase from 
Methanocaldococcus jannaschii.[80, 94, 95] 
As covered in detail in previous chapter, site-specific genetic incorporation system 
offers several advantages over other commonly used techniques to achieve the same goal 
such as native chemical ligation (NCL), expressed protein ligation (EPL) and use of 
auxotrophic bacterial strains.[32, 33, 96] These methods have limitations on the possible 
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modifications, sites that can be modified, the length of the peptide that can be synthesized 
(EPL and NCL) and drawbacks such as misincorporation and limitations due to toxicity 
of the ncAA being incorporated (auxotrophic strains).[34, 47, 97]  Although the site-specific 
ncAA genetic incorporation technique overcomes these major disadvantages and has 
evolved over the last few years to incorporate an extensive repertoire and diverse group 
of amino acids with various functional groups, its major shortcoming that remains to be 
addressed is the overall poor efficiency of these different ncAAs incorporation and low 
protein expression yield obtained with ncAA incorporated product.[98] The factors 
affecting the incorporation efficiency range from ncAA solubility to the efficiency of the 
PylRS system itself in generating sufficient charged ncAA-tRNAPyl. The aim of our study 
was to target the latter factor mentioned above by engineering the synthetase to improve 
the incorporation efficiency of the system. Previous approaches to resolve this issue have 
involved utilizing methods to evolve tRNAPyl to optimize the interaction between the 
pyrrolysyl-synthetase and tRNAPyl.[99] 
For our study, we chose to focus on the Methanosarcina mazei pyrrolysyl-
tRNA/synthetase (mm tRNAPyl/PylRS), which we have used to incorporate various 
phenylalanine, lysine and histidine derivatives, as described in the next chapter.[100-102] 
This archaeal synthetase is encoded by pylS gene and its catalytic C-terminal domain is 
well studied with resolved crystal structure (PDB: 2E3C) (Figure I-9).[73, 103] Unlike other 
synthetases, PylRS has high promiscuity and low selectivity towards substrates rendering 
it suitable for incorporation of a wide variety of ncAAs by mutating a few key residues on 
its catalytic domain.[104] The N-terminal domain of the synthetase, however, remains 
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relatively inadequately studied due to the hydrophobic nature of this domain which renders 
the protein unstable for crystallization.[85] To obtain higher amounts of charged ncAA-
tRNAPyl, a simple solution would be to express larger amount of PylRS. However,  due to 
the insoluble nature of the PylRS, it cannot be overexpressed in the system to improve the 
ncAA incorporation efficiency as it precipitates out in the expression media. It was shown 
in a recent study by R. Jiang et al. (2012) that the N-terminal domain of Methanosarcina 
barkeri PylRS plays a role in binding tRNAPyl thus elucidating its relatively unknown 
function. [92] In this study, they identified the key nucleotide residues on the D-stem, TψC 
loop and the variable loop of bacterial tRNAPyl (from Desulfitobacterium hafniense) which 
interact with bacterial homologs of the N-terminal and C-terminal domains of the mm 
pyrrolysyl-tRNA synthetase (Figure II-1). All these interactions between tRNAPyl and N-
terminal domain of synthetase are present distal from the acceptor stem, which is 
responsible for aminoacylation with ncAA. We thus chose to target the N-terminal domain 
of M. mazei PylRS, as it is unlikely to compromise the aminoacylation of the tRNAPyl, to 
improve its interaction with the tRNAPyl and hence the ncAA incorporation efficiency.  
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Figure II-1. D. hafniense tRNAPyl showing key bases involved in 
binding the C-terminal domain and the N-terminal domain of the 
bacterial PylRS. 
 34 
 
We employed a screening strategy to identify mutations on the N-terminal domain 
of the PylRS based on this scheme and is discussed in detail later. As most PylRS mutants 
developed for incorporation of specific ncAAs have their mutations on the C-terminal 
domain of the PylRS, can be simply transferred to other PylRS mutant synthetases for 
improving incorporation efficiency of their corresponding ncAAs. To test this, the 
mutations identified on the optimized system were then transposed to AcKRS, a 
pyrrolysyl-synthetase variant, used to incorporate the post-translational modification 
acetyl lysine into histone protein and tested the deacetylase activity of Sirtuin 1 (SIRT1) 
enzyme on histone tetramer. The SIRT1 enzyme belongs to NAD-dependent histone 
deacetylase (HDAC) family.[105] Among the 7 sirtuins (SIRT1-7) belonging to this HDAC 
family, SIRT1 is localized in nucleus and has been shown to target acetylated histone sites 
such as histones H3K9, H3K56 and H4K16 in vitro.[106, 107] As discussed later,  we tested 
the activity of this enzyme on reconstituted H3-H4 tetramer with acetylated H3K23 using 
the optimized AcKRS. 
 
Experimental Details 
Error-Prone PCR (EP-PCR) Conditions 
All the dNTPs and buffer used for the PCR reaction were purchased from Thermo 
Fischer Scientific®, the oligo primers were purchased from Integrated DNA Technology®. 
The reactions were performed on C1000TM Thermo Cycler from Bio-Rad® with the 
following thermocycling conditions: Initial denaturation- 95°C for 30 seconds, 25 cycles 
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with 56°C for 30s, 68°C for 90s, followed by final extension- 68°C for 5 minutes. Each 
PCR reaction consisted of following contents listed below: 
10x Thermo® Buffer 10 µl 
50x dNTP mix 2 µl 
100 mM dCTP 1 µl 
100 mM dTTP                       1 µl 
50 mM MgCl2 14 µl 
50 mM MnCl2 1 µl 
DNA template 2 µl 
Primer- f (100 µM) 1 µl 
Primer- r (100 µM) 1 µl 
Taq Polymerase (50) 1 µl 
H2O    66 µl 
 100 µl 
 
Library Construction and Selection 
Codon optimized M. mazei PylRS sequence (in pEVOL vector) was used as the 
template for construction of library using EP-PCR.[108] The mm PylRS sequence gene was 
amplified from pEVOL-mm PylRS-PylT plasmid by primers, Opt- mmPylRS-SpeI-F and 
Opt- mmPylRS-BstXI-R using the EP-PCR reaction conditions as mentioned above to 
introduce random mutations on the N-terminal domain of the synthetase sequence. The 
primers were designed to amplify the N-terminal tail. The pEVOL vector was amplified 
using the primers pEVOL-Opt- mmPylRS-BstXI-F and pEVOL-Opt- mmPylRS-SpeI-R 
to introduce restriction digestion cutting sites in the vector (Figure II-2). The gene product 
was then digested by SpeI and BstXI restriction enzymes (purchased from NEB®), purified 
and ligated into the amplified pEVOL vector digested by SpeI and BstXI to generate 
plasmid pEVOL-R1-mm PylRS-PylT plasmid. The generated library was directly used to 
transform E. coli Top10 pBAD sfGFP N134TAG cells using electroporation.  
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Figure II-2. Plasmid map of pEVOL mm PylRS-PylT showing the site 
on N-terminal tail for library generation. 
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The transformed cells were plated on screening plates containing LB agar, 
supplemented with Chloramphenicol (Cm, 34 μg/mL), Ampicillin (Amp, 100 μg/mL), 
0.2% Arabinose and ncAA (0.2 mM BocK). Plates were incubated at 37°C overnight. The 
cell phenotypic differences of viability and fluorescence intensity were analyzed and 
photographed (Figure II-3). The clones with strong fluorescence on the ncAA containing 
plate were selected as the active clones and were amplified. The pEVOL plasmid of the 
active clones was isolated and sequenced. 
The entire process of library construction and selection was repeated 3 times with 
the best clone from each round selected as template for the next round. 
All the plasmid sequences were confirmed by DNA sequencing (Table II-1). All 
oligonucleotide primers were purchased from Integrated DNA Technologies, Inc. 
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Figure II-3. Screening plate (Amp, Cm, 0.2% arabinose and 0.2 mM 
BocK) with 10-8 dilution of cloned library plated (Round 3). 
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Table II-1. Sequencing results of few clones from Round I, II and III of selection.  
Clone Name  Mutations 
R1-6 mm PylRS N121R 
R1-7 mm PylRS R19H 
R2-13 mm PylRS R19H, T56S, K109E, T121S 
R2-23 mm PylRS R19H, H29R 
R2-26 mm PylRS R19H, I36N, M40T, R113H, Q125R 
R3-1 mm PylRS R19H, H29R, K67Q, K106E, M108K, E123V 
R3-3 mm PylRS R19H, H29R, S111P 
R3-7 mm PylRS R19H, H28R, H29R, V31A, S32N, K105E, T122S 
R3-8 mm PylRS R19H, K27Q, H29R, T122S 
R3-10 mm PylRS 
R19H, K25E, H28Q, H29R, D78H, T122S, S160T, 
D206H, S209T 
R3-11 mm PylRS R19H, H29R, T122S 
R3-12 mm PylRS R19H, K25D, H29R, R33L, N87D, T122S, Q194H 
R3-14 mm PylRS R19H, H28R, H29R, K96E, T122S 
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Primer List 
Opt- mmPylRS-SpeI-F, 5’-GGA ATT ACT AGT ATG GAT AAG AAA CCG C-3’ 
Opt- mmPylRS-BstXI-R, 5’-TTA GAA CCA GAC GGC TGG GCC TGT GC-3’ 
pEVOL-Opt- mmPylRS-BstXI-F, 5’- ACA GGC CCA GCC GTC TGG TTC TAA G -3’ 
pEVOL-Opt- mmPylRS-SpeI-R, 5’- ATC CAT ACT AGT AAT TCC TCC TGT TA -3’ 
PylRS L301M Y306L L309A F, 5’- ATG GCA CCG AAC CTG CTG AAT TAC GCA 
CGT AAA -3’  
PylRS L301M Y306L L309A R, 5’- CAT CGG ACG CAG GCA GAA GTT CTT GTC 
CAC -3’  
PylRS C348F F, 5’- CAG ATG GGT TCT GGC TGC AC -3’  
PylRS C348F R, 5’- AAA AAA GTT CAG CAT AGT GAA CTC TTC C -3’ 
Opt mmpylRS L309T F, 5’- CGT AAA CTG GAT CGT GCA CTG CCG -3’ 
Opt mmpylRS L309T R, 5’- GGT GTA ATT GTA CAG GTT CGG TGC CAG C -3’ 
Opt mmpylRS C348G F, 5’- CAG ATG GGT TCT GGC TGC AC -3’ 
Opt mmpylRS C348G R, 5’- ACC AAA GTT CAG CAT AGT GAA CTC TTC C -3’ 
Opt mmpylRS Y384F F, 5’ - GGT GAC ACT CTG GAC GTT ATG CAT -3’ 
Opt mmpylRS Y384F R, 5’- GAA AAC CAT GCA GGA ATC ACC AAC -3’ 
pET28a-SUMO-NcoI-F, 5’ - GGA GAT ATA CCA TGG GCA GCA GCC -3’ 
pET28a-SUMO-BamHI-R, 5’ - GAC GGG ATC CAC CAC CAA TCT GTT C -3’ 
TEV-hH4-del-F, 5’- GAA AAT CTG TAC TTC CAG TCT GGT -3’ 
TEV-hH4-del-R, 5’- GGA TCC TGG CTG TGG TGA T -3’ 
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Plasmid Construction 
 
Construction of pEVOL mm AcKRS-PylT and pEVOL mm AcdKRS-PylT: 
To construct pEVOL mm AcKRS-PylT (R3-11), mutations were generated on 
pEVOL mm PylRS-PylT (R3-11) by site-directed mutagenesis, using the following 
primers: PylRS L301M Y306L L309A F, PylRS L301M Y306L L309A R, PylRS C348F 
F and PylRS C348F R. The sequence of the generated plasmid was confirmed using DNA 
sequencing. 
 Similarly, for construction of pEVOL mm AcdKRS-PylT (R3-11), mutations were 
generated on pEVOL mm PylRS-PylT (R3-11) by site-directed mutagenesis, using the 
following primers: Opt mmpylRS L309T F, Opt mmpylRS L309T R, Opt mmpylRS 
C348G F, Opt mmpylRS C348G R, Opt mmpylRS Y384F F and Opt mmpylRS Y384F 
R. The plasmid sequence of the plasmid generated was also confirmed by DNA 
sequencing. All the primers used in this experiment were purchased from Integrated DNA 
Technologies Inc. 
 
Construction of pETDuetI-His6x-SUMO-TEV-H4 plasmid: 
For construction of pETDuetI-His6x-SUMO-TEV-H4 plasmid (Figure II-4), 
His6x-SUMO fragment was amplified using pET28a-SUMO-NcoI-F and pET28a-
SUMO-BamHI-R primers to introduce NcoI and BamHI restriction digestion sites on the 
amplified fragment. TEV-hH4-del-F and TEV-hH4-del-R primers were used for deleting 
a nucleotide from pETDuetI-sfGFP-TEV-hH4 plasmid to account for frame shift.  
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Both the plasmid and amplified fragment were digested using NcoI and BamHI 
restriction enzymes and ligated to generate histone H4 plasmid with SUMO attached on 
the N-terminal tail of the histone. The plasmid sequence was confirmed by DNA 
sequencing. All the primers used were purchased from Integrated DNA Technologies Inc. 
 
 
 
 
 
 
 
  
Figure II-4. Plasmid map of pETDuetI His6x-SUMO-TEV-hH4 constructed. 
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DNA Sequences 
 
M. mazei PylRS:  
atggataagaaaccgctgaatactctgatttctgcaactggtctgtggatgagccgtaccggcaccatccacaagatcaaacac
cacgaggtttcccgtagcaaaatctacatcgaaatggcgtgcggtgaccacctggtggtaaacaactcccgttcttctcgtactg
cacgtgctctgcgccaccacaagtaccgtaagacctgcaagcgctgtcgcgtgtctgatgaagacctgaacaaattcctgacta
aagcgaacgaagatcagacttctgtgaaggtgaaagttgtttctgccccaacccgcaccaagaaagcgatgccgaagtccgtt
gcacgcgctccgaaaccgctggagaacaccgaagccgcacaggcccagccgtctggttctaagttttctccggcaatcccgg
tttctactcaggagtctgtgtctgtgccagcttctgttagcacttctatttcctctatcagcactggtgcgactgcgtccgctctggta
aaaggtaacactaacccgatcaccagcatgtctgctccggttcaggcttctgcaccggcactgactaaaagccagactgaccgt
ctggaggttctgctgaacccgaaagatgaaatcagcctgaactctggcaaaccgttccgtgaactggaatccgaactgctgtct
cgtcgtaagaaagacctgcaacaaatctatgctgaagagcgtgaaaactacctgggtaaactggaacgtgaaatcacccgtttc
tttgtggaccgtggtttcctggaaatcaagtctccgatcctgatcccgctggaatacatcgagcgcatgggtattgataacgacac
cgaactgtccaagcagattttccgtgtggacaagaacttctgcctgcgtccgatgctggcaccgaacctgtacaattacctgcgt
aaactggatcgtgcactgccggacccgatcaaaatctttgaaatcggtccatgctatcgtaaggagagcgacggtaaagaaca
cctggaagagttcactatgctgaacttttgtcagatgggttctggctgcacccgtgaaaatctggaatctatcatcaccgacttcct
gaaccacctgggcattgacttcaaaatcgttggtgattcctgcatggtttacggtgacactctggacgttatgcatggtgatctgga
actgagcagcgctgttgtgggtccgattccgctggatcgtgaatggggtatcgataaaccgtggattggtgctggcttcggtctg
gaacgtctgctgaaagttaagcacgactttaagaacatcaaacgtgctgcgcgttccgagtcctattacaacggcattagcacta
acctgtaa  
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M. mazei AcKRS: 
atggataagaaaccgctgaatactctgatttctgcaactggtctgtggatgagccgtaccggcaccatccacaagatcaaacac
cacgaggtttcccgtagcaaaatctacatcgaaatggcgtgcggtgaccacctggtggtaaacaactcccgttcttctcgtactg
cacgtgctctgcgccaccacaagtaccgtaagacctgcaagcgctgtcgcgtgtctgatgaagacctgaacaaattcctgacta
aagcgaacgaagatcagacttctgtgaaggtgaaagttgtttctgccccaacccgcaccaagaaagcgatgccgaagtccgtt
gcacgcgctccgaaaccgctggagaacaccgaagccgcacaggcccagccgtctggttctaagttttctccggcaatcccgg
tttctactcaggagtctgtgtctgtgccagcttctgttagcacttctatttcctctatcagcactggtgcgactgcgtccgctctggta
aaaggtaacactaacccgatcaccagcatgtctgctccggttcaggcttctgcaccggcactgactaaaagccagactgaccgt
ctggaggttctgctgaacccgaaagatgaaatcagcctgaactctggcaaaccgttccgtgaactggaatccgaactgctgtct
cgtcgtaagaaagacctgcaacaaatctatgctgaagagcgtgaaaactacctgggtaaactggaacgtgaaatcacccgtttc
tttgtggaccgtggtttcctggaaatcaagtctccgatcctgatcccgctggaatacatcgagcgcatgggtattgataacgacac
cgaactgtccaagcagattttccgtgtggacaagaacttctgcctgcgtccgatgatggcaccgaacctgctgaatctggcgcgt
aaactggatcgtgcactgccggacccgatcaaaatctttgaaatcggtccatgctatcgtaaggagagcgacggtaaagaaca
cctggaagagttcactatgctgaacttttttcagatgggttctggctgcacccgtgaaaatctggaatctatcatcaccgacttcctg
aaccacctgggcattgacttcaaaatcgttggtgattcctgcatggtttacggtgacactctggacgttatgcatggtgatctggaa
ctgagcagcgctgttgtgggtccgattccgctggatcgtgaatggggtatcgataaaccgtggattggtgctggcttcggtctgg
aacgtctgctgaaagttaagcacgactttaagaacatcaaacgtgctgcgcgttccgagtcctattacaacggcattagcactaa
cctgtaa 
 
M. mazei AcdKRS: 
atggataagaaaccgctgaatactctgatttctgcaactggtctgtggatgagccgtaccggcaccatccacaagatcaaacac
cacgaggtttcccgtagcaaaatctacatcgaaatggcgtgcggtgaccacctggtggtaaacaactcccgttcttctcgtactg
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cacgtgctctgcgccaccacaagtaccgtaagacctgcaagcgctgtcgcgtgtctgatgaagacctgaacaaattcctgacta
aagcgaacgaagatcagacttctgtgaaggtgaaagttgtttctgccccaacccgcaccaagaaagcgatgccgaagtccgtt
gcacgcgctccgaaaccgctggagaacaccgaagccgcacaggcccagccgtctggttctaagttttctccggcaatcccgg
tttctactcaggagtctgtgtctgtgccagcttctgttagcacttctatttcctctatcagcactggtgcgactgcgtccgctctggta
aaaggtaacactaacccgatcaccagcatgtctgctccggttcaggcttctgcaccggcactgactaaaagccagactgaccgt
ctggaggttctgctgaacccgaaagatgaaatcagcctgaactctggcaaaccgttccgtgaactggaatccgaactgctgtct
cgtcgtaagaaagacctgcaacaaatctatgctgaagagcgtgaaaactacctgggtaaactggaacgtgaaatcacccgtttc
tttgtggaccgtggtttcctggaaatcaagtctccgatcctgatcccgctggaatacatcgagcgcatgggtattgataacgacac
cgaactgtccaagcagattttccgtgtggacaagaacttctgcctgcgtccgatgctggcaccgaacctgtacaattacacccgt
aaactggatcgtgcactgccggacccgatcaaaatctttgaaatcggtccatgctatcgtaaggagagcgacggtaaagaaca
cctggaagagttcactatgctgaactttggtcagatgggttctggctgcacccgtgaaaatctggaatctatcatcaccgacttcct
gaaccacctgggcattgacttcaaaatcgttggtgattcctgcatggttttcggtgacactctggacgttatgcatggtgatctgga
actgagcagcgctgttgtgggtccgattccgctggatcgtgaatggggtatcgataaaccgtggattggtgctggcttcggtctg
gaacgtctgctgaaagttaagcacgactttaagaacatcaaacgtgctgcgcgttccgagtcctattacaacggcattagcacta
acctgtaa 
 
PylT: 
ggaaacctgatcatgtagatcgaatggactctaaatccgttcagccgggttagattcccggggtttccgcca 
 
sfGFP N134TAG: 
atggttagcaaaggtgaagaactgtttaccggcgttgtgccgattctggtggaactggatggtgatgtgaatggccataaatttag
cgttcgtggcgaaggcgaaggtgatgcgaccaacggtaaactgaccctgaaatttatttgcaccaccggtaaactgccggttcc
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gtggccgaccctggtgaccaccctgacctatggcgttcagtgctttagccgctatccggatcatatgaaacgccatgatttcttta
aaagcgcgatgccggaaggctatgtgcaggaacgtaccattagcttcaaagatgatggcacctataaaacccgtgcggaagtt
aaatttgaaggcgataccctggtgaaccgcattgaactgaaaggtattgattttaaagaatagggcaacattctgggtcataaact
ggaatataatttcaacagccataatgtgtatattaccgccgataaacagaaaaatggcatcaaagcgaactttaaaatccgtcaca
acgtggaagatggtagcgtgcagctggcggatcattatcagcagaataccccgattggtgatggcccggtgctgctgccggat
aatcattatctgagcacccagagcgttctgagcaaagatccgaatgaaaaacgtgatcatatggtgctgctggaatttgttaccgc
cgcgggcattacccacggtatggatgaactgtataaaggcagccaccatcatcatcaccattaa 
 
His6x-TEV-hH3: 
catcaccatcatcaccacagccaggatccggaaaatctgtacttccaggctcgcaccaaacagactgctcgtaagtccactggc
ggtaaagcgccgcgtaaacagctggcaaccaaggcagcgcgtaaaagcgctccagctactggcggcgtgaagaagccgca
ccgttatcgcccgggtactgtggctctgcgtgaaatccgccgctaccagaaaagcaccgaactgctgattcgcaaactgccattt
caacgtctggttcgcgaaattgctcaggatttcaaaaccgacctgcgcttccagtctagcgctgtgatggcactgcaagaggcgt
ctgaggcatatctggttggcctgttcgaagataccaacctgtgcgcaatccatgcaaagcgtgtaaccattatgccgaaagacat
ccaactggctcgtcgtatccgtggtgagcgtgcgtga 
 
His6x-SUMO-TEV-hH4: 
Atgggcagcagccatcatcatcatcatcacagcagcggcctggtgccgcgcggcagccatatgtcggactcagaagtcaatc
aagaagctaagccagaggtcaagccagaagtcaagcctgagactcacatcaatttaaaggtgtccgatggatcttcagagatct
tcttcaagatcaaaaagaccactcctttaagaaggctgatggaagcgttcgctaaaagacagggtaaggaaatggactccttaa
gattcttgtacgacggtattagaattcaagctgatcagacccctgaagatttggacatggaggataacgatattattgaggctcac
agagaacagattggtggtggatccgaaaatctgtacttccagtctggtcgtggtaaaggtggtaaaggcctgggtaaaggtggt
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gctaagcgtcaccgtaaagtgctgcgcgacaacatccagggtatcaccaaaccagctattcgccgtctggcacgtcgcggtgg
tgtgaaacgcatcagcggtctgatctatgaagaaacccgtggtgttctgaaagtatttctggagaacgttatccgcgatgcggtg
acctacaccgaacacgcgaaacgtaagaccgttactgctatggatgttgtgtacgctctgaaacgccagggtcgtactctgtac
ggtttcggtggctga 
 
SIRT1: 
gcggacgaggcggccctcgcccttcagcccggcggctccccctcggcggcgggggccgacagggaggccgcgtcgtccc
ccgccggggagccgctccgcaagaggccgcggagagatggtcccggcctcgagcggagcccgggcgagcccggtggg
gcggccccagagcgtgaggtgccggcggcggccaggggctgcccgggtgcggcggcggcggcgctgtggcgggaggc
ggaggcagaggcggcggcggcaggcggggagcaagaggcccaggcgactgcggcggctggggaaggagacaatggg
ccgggcctgcagggcccatctcgggagccaccgctggccgacaacttgtacgacgaagacgacgacgacgagggcgagg
aggaggaagaggcggcggcggcggcgattgggtaccgagataaccttctgttcggtgatgaaattatcactaatggttttcattc
ctgtgaaagtgatgaggaggatagagcctcacatgcaagctctagtgactggactccaaggccacggataggtccatatactttt
gttcagcaacatcttatgattggcacagatcctcgaacaattcttaaagatttattgccggaaacaatacctccacctgagttggat
gatatgacactgtggcagattgttattaatatcctttcagaaccaccaaaaaggaaaaaaagaaaagatattaatacaattgaaga
tgctgtgaaattactgcaagagtgcaaaaaaattatagttctaactggagctggggtgtctgtttcatgtggaatacctgacttcag
gtcaagggatggtatttatgctcgccttgctgtagacttcccagatcttccagatcctcaagcgatgtttgatattgaatatttcagaa
aagatccaagaccattcttcaagtttgcaaaggaaatatatcctggacaattccagccatctctctgtcacaaattcatagccttgtc
agataaggaaggaaaactacttcgcaactatacccagaacatagacacgctggaacaggttgcgggaatccaaaggataattc
agtgtcatggttcctttgcaacagcatcttgcctgatttgtaaatacaaagttgactgtgaagctgtacgaggagatatttttaatcag
gtagttcctcgatgtcctaggtgcccagctgatgaaccgcttgctatcatgaaaccagagattgtgttttttggtgaaaatttaccag
aacagtttcatagagccatgaagtatgacaaagatgaagttgacctcctcattgttattgggtcttccctcaaagtaagaccagtag
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cactaattccaagttccataccccatgaagtgcctcagatattaattaatagagaacctttgcctcatctgcattttgatgtagagctt
cttggagactgtgatgtcataattaatgaattgtgtcataggttaggtggtgaatatgccaaactttgctgtaaccctgtaaagctttc
agaaattactgaaaaacctccacgaacacaaaaagaattggcttatttgtcagagttgccacccacacctcttcatgtttcagaag
actcaagttcaccagaaagaacttcaccaccagattcttcagtgattgtcacacttttagaccaagcagctaagagtaatgatgatt
tagatgtgtctgaatcaaaaggttgtatggaagaaaaaccacaggaagtacaaacttctaggaatgttgaaagtattgctgaaca
gatggaaaatccggatttgaagaatgttggttctagtactggggagaaaaatgaaagaacttcagtggctggaacagtgagaaa
atgctggcctaatagagtggcaaaggagcagattagtaggcggcttgatggtaatcagtatctgtttttgccaccaaatcgttaca
ttttccatggcgctgaggtatattcagactctgaagatgacgtcttatcctctagttcttgtggcagtaacagtgatagtgggacatg
ccagagtccaagtttagaagaacccatggaggatgaaagtgaaattgaagaattctacaatggcttagaagatgagcctgatgtt
ccagagagagctggaggagctggatttgggactgatggagatgatcaagaggcaattaatgaagctatatctgtgaaacagga
agtaacagacatgaactatccatcaaacaaatcatag 
 
Protein Sequences 
 
M. mazei PylRS: 
MDKKPLNTLI SATGLWMSRT GTIHKIKHHE VSRSKIYIEM ACGDHLVVNN 
SRSSRTARAL RHHKYRKTCK RCRVSDEDLN KFLTKANEDQ TSVKVKVVSA 
PTRTKKAMPK SVARAPKPLE NTEAAQAQPS GSKFSPAIPV STQESVSVPA 
SVSTSISSIS TGATASALVK GNTNPITSMS APVQASAPAL TKSQTDRLEV 
LLNPKDEISL NSGKPFRELE SELLSRRKKD LQQIYAEERE NYLGKLEREI 
TRFFVDRGFL EIKSPILIPL EYIERMGIDN DTELSKQIFR VDKNFCLRPM 
LAPNLYNYLR KLDRALPDPI KIFEIGPCYR KESDGKEHLE EFTMLNFCQM 
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GSGCTRENLE SIITDFLNHL GIDFKIVGDS CMVYGDTLDV MHGDLELSSA 
VVGPIPLDRE WGIDKPWIGA GFGLERLLKV KHDFKNIKRA ARSESYYNGI 
STNL 
 
M. mazei AcKRS: 
MDKKPLNTLI SATGLWMSRT GTIHKIKHHE VSRSKIYIEM ACGDHLVVNN 
SRSSRTARAL RHHKYRKTCK RCRVSDEDLN KFLTKANEDQ TSVKVKVVSA 
PTRTKKAMPK SVARAPKPLE NTEAAQAQPS GSKFSPAIPV STQESVSVPA 
SVSTSISSIS TGATASALVK GNTNPITSMS APVQASAPAL TKSQTDRLEV 
LLNPKDEISL NSGKPFRELE SELLSRRKKD LQQIYAEERE NYLGKLEREI 
TRFFVDRGFL EIKSPILIPL EYIERMGIDN DTELSKQIFR VDKNFCLRPM 
MAPNLLNLAR KLDRALPDPI KIFEIGPCYR KESDGKEHLE EFTMLNFFQM 
GSGCTRENLE SIITDFLNHL GIDFKIVGDS CMVYGDTLDV MHGDLELSSA 
VVGPIPLDRE WGIDKPWIGA GFGLERLLKV KHDFKNIKRA ARSESYYNGI 
STNL 
 
M. mazei AcdKRS: 
MDKKPLNTLI SATGLWMSRT GTIHKIKHHE VSRSKIYIEM ACGDHLVVNN 
SRSSRTARAL RHHKYRKTCK RCRVSDEDLN KFLTKANEDQ TSVKVKVVSA 
PTRTKKAMPK SVARAPKPLE NTEAAQAQPS GSKFSPAIPV STQESVSVPA 
SVSTSISSIS TGATASALVK GNTNPITSMS APVQASAPAL TKSQTDRLEV 
LLNPKDEISL NSGKPFRELE SELLSRRKKD LQQIYAEERE NYLGKLEREI 
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TRFFVDRGFL EIKSPILIPL EYIERMGIDN DTELSKQIFR VDKNFCLRPM 
LAPNLYNYTR KLDRALPDPI KIFEIGPCYR KESDGKEHLE EFTMLNFGQM 
GSGCTRENLE SIITDFLNHL GIDFKIVGDS CMVFGDTLDV MHGDLELSSA 
VVGPIPLDRE WGIDKPWIGA GFGLERLLKV KHDFKNIKRA ARSESYYNGI 
STNL 
 
sfGFP N134X: 
MVSKGEELFT GVVPILVELD GDVNGHKFSV RGEGEGDATN GKLTLKFICT 
TGKLPVPWPT LVTTLTYGVQ CFSRYPDHMK RHDFFKSAMP EGYVQERTIS 
FKDDGTYKTR AEVKFEGDTL VNRIELKGID FKEXGNILGH KLEYNFNSHN 
VYITADKQKN GIKANFKIRH NVEDGSVQLA DHYQQNTPIG DGPVLLPDNH 
YLSTQSVLSK DPNEKRDHMV LLEFVTAAGI THGMDELYKG SHHHHHH 
X represents ncAA 
 
His6x-TEV-hH3: 
HHHHHHSQD PENLYFQART KQTARKSTGG KAPRKQLATK AARKSAPATG 
GVKKPHRYRP GTVALREIRR YQKSTELLIR KLPFQRLVRE IAQDFKTDLR 
FQSSAVMALQ EASEAYLVGL FEDTNLCAIH AKRVTIMPKD IQLARRIRGE RA 
 
His6x-SUMO-TEV-hH4: 
MGSSHHHHHH SSGLVPRGSH MSDSEVNQEA KPEVKPEVKP ETHINLKVSD 
GSSEIFFKIK KTTPLRRLME AFAKRQGKEM DSLRFLYDGI RIQADQTPED 
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LDMEDNDIIE AHREQIGGGS ENLYFQSGRG KGGKGLGKGG AKRHRKVLRD 
NIQGITKPAI RRLARRGGVK RISGLIYEET RGVLKVFLEN VIRDAVTYTE 
HAKRKTVTAM DVVYALKRQG RTLYGFGG 
 
SIRT1: 
ADEAALALQ PGGSPSAAGA DREAASSPAG EPLRKRPRRD GPGLERSPGE 
PGGAAPEREV PAAARGCPGA AAAALWREAE AEAAAAGGEQ EAQATAAAGE 
GDNGPGLQGP SREPPLADNL YDEDDDDEGE EEEEAAAAAI GYRDNLLFGD 
EIITNGFHSC ESDEEDRASH ASSSDWTPRP RIGPYTFVQQ HLMIGTDPRT 
ILKDLLPETI PPPELDDMTL WQIVINILSE PPKRKKRKDI NTIEDAVKLL 
QECKKIIVLT GAGVSVSCGI PDFRSRDGIY ARLAVDFPDL PDPQAMFDIE 
YFRKDPRPFF KFAKEIYPGQ FQPSLCHKFI ALSDKEGKLL RNYTQNIDTL 
EQVAGIQRII QCHGSFATAS CLICKYKVDC EAVRGDIFNQ VVPRCPRCPA 
DEPLAIMKPE IVFFGENLPE QFHRAMKYDK DEVDLLIVIG SSLKVRPVAL 
IPSSIPHEVP QILINREPLP HLHFDVELLG  DCDVIINELC HRLGGEYAKL 
CCNPVKLSEI TEKPPRTQKE LAYLSELPPT PLHVSEDSSS PERTSPPDSS 
VIVTLLDQAA KSNDDLDVSE SKGCMEEKPQ EVQTSRNVES IAEQMENPDL   
KNVGSSTGEK NERTSVAGTV RKCWPNRVAK EQISRRLDGN QYLFLPPNRY 
IFHGAEVYSD SEDDVLSSSS CGSNSDSGTC QSPSLEEPME DESEIEEFYN 
GLEDEPDVPE RAGGAGFGTD GDDQEAINEA ISVKQEVTDM NYPSNKS 
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Expression and Purification of sfGFP-N134X 
For expression of sfGFP N134X, where X is BocK, AcK or AcdK, the following 
expression and purification protocol was followed. To express sfGFP N134BocK, the 
plasmid pEVOL mm PylRS (WT, R1-7, R2-23 and R3-11) was used together with pBAD 
sfGFP N134TAG to co-transform E. coli Top10 cells. The cells were grown in a 5 mL LB 
medium containing 100 µg/mL ampicillin (Amp) and 34 µg/mL chloramphenicol (Cm), 
overnight. The overnight culture was further used to inoculate into a 200 mL 2YT medium 
with the same concentration of Amp and Cm. Cells were grown in a 37°C shaker (250 
r.p.m.) to OD600 0.4 - 0.6. The protein expression was induced by the addition of 0.2% 
arabinose and 0.2 mM BocK as the final concentration. After 12 h expression, the cells 
were harvested (4k 20 min, 4°C), washed, and fully resuspended with a lysis buffer (300 
mM NaCl, 50 mM NaH2PO4, 10 mM imidazole, pH 7.5). The sonication of cells 
underwent under ice/water incubation for 3 times (2 min each time with an interval of 5 
min). Then the cell lysate was centrifuged (10k 40 min, 4°C), and the supernatant was 
collected. 1 mL Ni SepharoseTM 6 Fast Flow column (GE Healthcare) was added to the 
supernatant and incubated for 1 h at 4°C. The mixture was loaded to a column and the 
flow-through was removed. 15 mL of wash buffer (300 mM NaCl, 50 mM NaH2PO4, 20 
mM imidazole, pH 7.5) was used to wash the protein-bound resin in three batches followed 
by 5 mL of elution buffer (300 mM NaCl, 50 mM NaH2PO4, 250 mM imidazole, pH 7.5) 
to elute the target protein. All the eluted fractions were collected and concentrated by 
Amicon Ultra-15 Centrifugal Filter Device (10k MWCO, Millipore), and dialyzed in 20 
mM phosphate pH 8.5 buffer 3 times. FPLC Q-Sepharose anion exchange column was 
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used to further purify the sfGFP N134BocK protein. The elution samples were collected 
and again concentrated by Amicon Ultra-15 Centrifugal Filter Device (10k MWCO, 
Millipore). For expression of sfGFP N134AcK, similar procedure was followed, except 
for addition of 5 mM nicotinamide and 5 mM AcK instead of BocK at the induction stage. 
For expression of sfGFP N134AcdK, 1 mM AcdK was added instead of BocK and same 
procedure was followed for purification. The protein expressions were analyzed on 12% 
SDS-PAGE and quantified using BCA Assay.  
 
Expression and Purification of H3K23AcK 
To express H3K23AcK protein, pEVOL mm AcKRS-PylT (WT or R3-11) and 
pETDuet-1 His6x-TEV-H3K23TAG were used to transform E. coli BL21 (DE3) cells. 
Cells were grown in 2YT media supplemented with Cm (34 μg/mL) and Amp (100 
μg/mL), to OD600 0.4−0.6, and the expression of H3K23AcK was induced with the 
addition of 5 mM Nꜫ-Acetyl-L-Lysine (Chem-Impex), 5 mM nicotinamide, 0.2% 
arabinose, and 1 mM IPTG for 12 h at 37 °C. Cells were then collected by centrifugation; 
resuspended in a lysis buffer containing 20 mM Tris-HCl (pH 7.5), 500 mM NaCl, 0.1% 
NaN3, and 0.1% Triton X-100; and then lysed by sonication. The cell lysate was 
centrifuged, and the pellet was collected. The collected pellet was then dissolved in a urea 
buffer containing 20 mM Tris-HCl (pH 7.5), 500 mM NaCl, and 6 M urea and cleared by 
centrifugation. The supernatant was then collected and further purified on Ni-NTA column 
(Ni-Sepharose 6 Fast Flow column from GE Healthcare). The column was washed with a 
wash buffer containing 20 mM Tris-HCl (pH 7.5), 500 mM NaCl, 20 mM imidazole, and 
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6 M urea and then eluted with a second buffer containing 20 mM Tris-HCl (pH 7.5), 500 
mM NaCl, 300 mM imidazole, and 6 M urea. Following purification, the proteins were 
analyzed on 15% SDS-PAGE and quantified using BCA Assay. 
 
Histone H4 Expression and Tetramer Refolding 
For tetramer construction, histone H4 was also expressed. Fusion gene coding an 
N-terminal His-tagged SUMO-linked to histone H4 with a TEV protease cleavage site 
between them was cloned into a pETduet-1 plasmid to increase H4 expression yield as 
mentioned above. The plasmid was used to transform BL21 (DE3) cells. The transformed 
cells were then grown in 2YT media supplemented with Cm (34 μg/mL) and Amp (100 
μg/mL), to OD600 0.4−0.6 and then supplemented with 1 mM IPTG to induce expression 
for 4 h at 37 °C. For protein purification, the same protocol was used as mentioned for 
H3K23AcK expression above. 
Histone His6x-SUMO-TEV-H4 protein was re-dissolved in 6M guanidinium 
chloride buffer (6 M guanidinium chloride, 20 mM Tris, 250 mM NaCl, pH 8.0) and mixed 
with Histone His-TEV-H3 K23AcK solution (in histone elution buffer: 50 mM Tris-HCl, 
100 mM NaCl, 250 mM imidazole, 6 M Urea, pH 7.8) in a 1:1 molar ratio. Total protein 
concentration was adjusted to 2 µg/µl. His-SUMO-TEV-H4 and His-TEV-H3 K23AcK 
mixture were dialyzed sequentially at 4°C in 2 M NaCl buffer (2 M NaCl, 20 mM Tris, 1 
mM EDTA, pH 7.5), 1 M NaCl (1 M NaCl, 20 mM Tris, 1 mM EDTA, pH 7.5) and 0.25 
M NaCl buffer (250 mM NaCl, 20 mM Tris, 1 mM EDTA, pH 7.5). Suspension was 
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centrifuged (13000g 10 min, Eppendorf AG minispin) at 4°C and supernatant was 
collected as the tetramer product. 
 
SIRT1 Deacetylation Assay 
The histone H3 K23AcK/H4 tetramer concentration was adjusted to 0.4 µM by 
adding 0.25 M NaCl buffer (250 mM NaCl, 20 mM Tris, 1 mM EDTA, pH 7.5).  NAD+ 
(1mM), DTT (1 mM) and His-SIRT1 (0.2 µM) (expressed using published protocol[109]) 
were also added to tetramer reaction solutions. After being incubated at 37°C for 3 h, the 
reaction mixture was directly subjected to 18% SDS-PAGE gel and transferred to 
nitrocellulose membrane with standard semi dry Western blot protocol (Bio-Rad Trans-
Blot Turbo transfer system). The membrane was coated with 5% fat-free milk (10 mL) for 
2 h at room temperature and then treated with pan-acetylation antibody from PTM bio-lab 
(#PTM-101) overnight at 4°C (1: 2000, 5 mL). The membrane then was washed with 
PBST (PBS with 0.1% Tween-20, 10 mL) on the shaker six times with 2 min intervals. 
The membrane was then treated with secondary antibody (1: 10000, 5 mL) from Jackson 
Immuno Research (West Grove, PA) at room temperature for 1 h. The membrane was then 
washed with PBST on the shaker three times with 2 min intervals. The results were then 
visualized with Pierce ECL Western Blotting Substrate (#32106). Images were taken by 
ChemiDoc XRS+ system from Bio-Rad (Hercules, CA). 
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AcdK Synthesis 
The following synthesis scheme[110] (Figure II-5) was followed for synthesis of Nϵ-
(4-azidobenzoxycarbonyl)-δ,ϵ-dehydrolysine (AcdK) by Dr. Yadagiri Kurra: 
To a 500-mL round bottom flask was added L-Glutamic acid (30 g, 0.2 mol), 
phthalic anhydride (29.6 g, 0.2 mol), triethylamine (2.79 mL, 0.02 mol) and toluene (250 
mL). The mixture was heated to reflux and the water formed in the reaction was collected 
using a Dean-Stark apparatus. After 24 h, the reaction was cooled to room temperature 
and solvent was removed under reduced pressure. Ethyl acetate (EtOAc) was added to 
dilute the reaction and pH was adjusted to 2 with HCl (3.0 M). Then the mixture was 
extracted with EtOAc (300 mL × 3) and the organic layers were dried, concentrated. The 
resulting solid was washed with EtOAc and then filtered to collect the solid. Drying under 
high vacuum of the solid afforded the N-protected L-Glutamic acid 1 (22.5 g, 41% yield). 
1 (22.5 g, 0.081 mol) was dissolved in MeOH (200 mL) and cooled to 0oC. SOCl2 
was added dropwise. The mixture was warmed to room temperature naturally and stirred 
overnight. All the volatiles were removed under reduced pressure and then diluted with 
EtOAc. The organic layer was washed with NaHCO3 aqueous and brine. Then dried and 
concentrated to give methyl ester 2 (25.4 g, 100%). 
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                                                                                                                [110] 
Figure II-5. Synthesis scheme of AcdK (Compound 9) 
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2 (25.4 g, 0.083 mol) was dissolved in anhydrous diethyl ether (300 mL), cooled 
to -78oC. DIBAL-H (99.8 mL, 1.0 M in hexane, 1.2 eq.) was added dropwise under Argon 
protection. Stirring continued for another 1h. Water (10 mL) was added, warmed to room 
temperature, and continue stirring for 1 h. The precipitate was removed through Celite and 
the filtrate was concentrated to produce the crude aldehyde 3, which was used directly to 
the next step without further purification. 
Anhydrous THF (80 mL) was added to a round-bottom flask, and cooled to 0oC. 
NaH (1.9 g, 60% dispersion in mineral oil, 1.2 eq.) was added carefully. Then tert-butyl 
2-(diethoxyphosphoryl) acetate (11.99 g, 1.2 eq.) was added dropwise. After bubble 
ceased to release, 3 (~ 0.0396 mol) in THF (20 mL) was added and the mixture was 
warmed to room temperature. After 2 h, NH4Cl aqueous was added to quench the reaction. 
After diethyl ether extraction, the organic phase was dried and concentrated. The residue 
was purified via column chromatography with hexanes/EtOAc (3:1 v/v) as eluent to give 
product 4 (6.9 g, 22% yield, two steps) 
4 (6.9 g, 0.0184788 mol) was dissolved in CH2Cl2 (70 mL), cooled to 0 
oC. 
Trifluoroacetic acid (14.15 mL, 10 eq.) was added dropwise. Then the solution was 
warmed to room temperature and stirred for 1.5 h. Diluted with CH2Cl2, washed with H2O, 
then dried and concentrated. The residue was purified via column chromatography with 
hexanes/ethyl acetate (1:1 v/v) as eluent to afford pure acid 5 (6.1 g, 85% yield). 
5 (5.0 g, 0.015758 mol) was dissolved in acetone (150 mL), cooled to 0 oC and 
then added diisopropylethylamine (6.587 mL, 2.4 eq.). Ethyl chloroformate (3.3 mL, 2.2 
eq.) was added dropwise and the solution was stirred at 0 oC for 1 h. Sodium azide (5.12 
 59 
 
g, 5 eq.) in water (25 mL) was added and the reaction mixture was warmed to room 
temperature. After 1h with stirring, brine was added and extracted with ethyl acetate. The 
organic layer was dried and concentrated. The residue was purified via column 
chromatography with hexanes/ethyl acetate (3:1 v/v) as eluent to afford pure acid 6 (4.6 
g, 85% yield). 
6 (4.6 g, 0.01344 mol) was dissolved in toluene, and heated to reflux for 2 h under 
Argon protection. Then (2-azidophenyl) methanol (2 g, 1.0 eq.) was added and the mixture 
continued refluxing for another 2 h under Argon protection. Cooled to room temperature, 
and the solvent was removed under reduced pressure and the residue was purified via 
column chromatography with hexanes/ethyl acetate (3:1 to 1:1 v/v) as eluent to afford 
product 7 (5.1 g, 92% yield). 
7 (5.1 g, 0.011 mol) was dissolved in ethanol/dichloromethane (16 mL/25 mL) and 
hydrazine monohydrate (0.85 mL, 1.6 eq.) was added. The mixture was stirred at room 
temperature overnight. The white solid formed in the reaction was filtered away and the 
filtrate was concentrated. The residue was purified via column chromatography with 
methanol/ammonium hydroxide/dichloromethane (15:50:450 v/v/v) as eluent to afford 
amine 8 (2.2 g, 60% yield). 
8 (2.2 g, 0.0066 mol) was dissolved in THF/H2O (25 mL/12.5 mL) and LiOH 
(0.3168 g, 2 eq.) was added. After stirring for 1 h, the undissolved impurities were filtered 
away and the filtrate was concentrated under vacuum to afford amino acid 9 (2.1 g, 96% 
yield). 1H NMR (CD3OD, 300 MHz) 7.40 (d, 2H, J = 4.5 Hz), 7.07 (d, 2H, J = 4.5 Hz), 
6.43 (dd, 1H, J = 0.9, 8.7 Hz), 5.12 (dd, 1H, J = 4.5, 8.7 Hz), 5.08 (s, 2H), 3.20 (dd, 1H, J 
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= 0.9, 4.2 Hz), 2.12-2.07 (m, 2H), 1.76-1.73 (m, 1H), 1.60-1.56 (m, 1H). 13C NMR 
(CD3OD, 75 MHz) 181.4, 154.6, 139.8, 133.6, 129.3, 123.9, 118.6, 110.4, 65.5, 55.7, 36.0, 
26.1.  
 
 
 
                                                                                                [110] 
 
 
  
Figure II-6. 1H-NMR data of compound 9. 
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Figure II-7. 13C-NMR data of compound 9. 
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Results and Discussion 
To target the N-terminal domain of the PylRS, a library of Methanosarcina mazei 
pyrrolysyl-synthetase was constructed with random mutations generated on the N-
terminal domain of the synthetase. A plasmid pEVOL-PylRS derived from a pEVOL 
vector developed by Schultz et. al.[111] was constructed to contain genes coding tRNAPyl 
under the control of the proK promoter and M. mazei PylRS under the control of the pBAD 
promoter. The PylRS gene was codon-optimized for expression in E. coli. Two restriction 
sites SpeI and BstXI were introduced around coding sites for the N-terminus methionine 
and residue S130, respectively. In order to create this library of M. mazei PylRS mutants, 
we utilized a technique known as error-prone PCR (EP-PCR)[108] which introduces 
random mutations in an amplified DNA sequence by taking advantage of Taq DNA 
polymerase’s low fidelity and by modulating the Mg2+, Mn2+ and dNTPs concentration in 
the PCR reaction. EP-PCR generated random mutations between M1 and S130 residues 
of the M. mazei PylRS. The mutants so generated were then co-transformed with super-
folder green fluorescence (sfGFP) reporter protein with mutation at N134TAG and 
screened in presence of an ncAA, Nϵ -(tert-butoxycarbonyl)-L-lysine (BocK) (Figure II-
8.), for selecting the mutants with high ncAA incorporation efficiency (screening strategy 
shown in Figure II-9). A previous test indicated that E. coli Top10 cells transformed with 
the original pEVOL-PylRS and pBAD-sfGFP134TAG plasmids displayed visible but low 
green fluorescence when grown in the presence of 0.2 mM BocK. We expected that mutant 
PylRS clones more active than the wild-type would lead to higher fluorescence of 
expressed sfGFP, leading to more fluorescently visible colonies on plates and several 
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clones were identified using this strategy. All the mutants were sequenced and the results 
compared with that of wild-type PylRS sequence. The mutant showing the highest 
efficiency (R1-7 mm PylRS), from this first round of selection had a mutation at R19H 
and was chosen as a template for generating a second library using EP-PCR and it was 
subjected to the same screening strategy. The DNA sequencing results showed that the 
mutations converge in each round of selection.The mutant from the second round of 
screening had an additional mutation at H29R. The entire cloning and screening process 
was repeated three times to obtain the most efficient mm PylRS mutant (R3-11 mm PylRS) 
from the third round of selection. This clone has an additional mutation at T122S along 
with the mutations present on R19H and H29R. The sequencing results from each round 
of the convergent sequences are as summarized in Table II-2. 
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Figure II-8. ncAAs used in the study 1. Nϵ -(tert-butoxycarbonyl)-L-lysine 
(BocK) 2. Nϵ -acetyl-L-lysine (AcK) 3. Nϵ -(4-azidobenzoxycarbonyl)-δ,ϵ-
dehydrolysine (AcdK). 
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Figure II-9. Strategy used for screening efficient N-terminal domain 
modified PylRS mutants in library generated by error prone PCR. 
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Table II-2. Sequencing results of the best mutants identified in each round of 
selection.  
Mutant Name  Mutations  
Wild-type mm PylRS[a]  --  
R1-7 mm PylRS[b] R19H   
R2-23 mm PylRS[c] R19H H29R  
R3-11 mm PylRS[d] R19H H29R T122S 
[a] codon optimized sequence. [b] 1st round of selection. [c] 2nd round of selection. 
[d] 3rd round of selection. 
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The efficiency of all three mutant clones (R1-7, R2-23 and R3-11 mm PylRS) and 
wild type PylRS for the genetic incorporation of BocK was further tested and compared 
on a larger scale. E. coli Top10 cells containing both pBAD-sfGFP134TAG and either of 
the four pEVOL plasmids containing a wild type or mutant PylRS gene (R1-7, R2-23 or 
R3-11 mm PylRS) were grown in LB medium supplemented with 0.2 mM BocK and the 
expression of full-length sfGFP was induced by the addition of 0.2% arabinose. The 
expressed sfGFP was then affinity-purified using the Ni-NTA resin and analyzed by SDS-
PAGE. Expression levels of sfGFP in four different cells were then quantified. As the 
results indicate, R3-11 mutant shows ~4 times increase in ncAA incorporation efficiency 
whereas mutants R1-2 and R2-23 show ~2 times and ~3 times increase in incorporation 
efficiency respectively. These results demonstrate our initial hypothesis of obtaining a 
better performing evolved PylRS clone by mutating N-terminal domain of PylRS that 
directly interacts with tRNAPyl. These results are summarized in Table II-3, Figure II-10. 
These observations encouraged us to further test if the mutations generated on the 
N-terminal domain on the PylRS mutant obtained from the final round of selection (R3-
11 mm PylRS) also increase the efficiency of the synthetase in incorporating other ncAAs. 
We tested this by replicating these mutations on the N-terminal domain of AcKRS[112, 113] 
which is a M. mazei PylRS derivative with a modified catalytic domain used for 
incorporating Nϵ-acetyl-L-lysine (AcK) (Figure II-8.) in proteins. The incorporation 
efficiency of the mutant mm AcKRS (Opt AcKRS) was first compared with that of the 
original AcKRS (Non-opt AcKRS) for incorporation of 5 mM AcK in sfGFP N134TAG 
and the protein expression levels quantified (Table II-3, Figure II-11). The mutations were 
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also generated on another M. mazei PylRS, AcdKRS[110] which has been used by us to 
incorporate Nϵ -(4-azidobenzoxycarbonyl)-δ,ϵ-dehydrolysine (AcdK) (Figure II-8.), a 
precursor for generating dimethyl lysine, in proteins. The optimized AcdKRS was 
compared with that of original AcdKRS in incorporating 1 mM AcdK in sfGFP N134TAG 
and the proteins were purified and the expression level quantified. The results are as 
summarized in Table II-3, Figure II-12.  
The introduction of R19H, H29R and T122S mutations to these two synthetases is 
not expected to interrupt their recognition of corresponding ncAAs. On the contrary, 
improved incorporation of ncAAs was foreseen. As predicted, in comparison to a pEVOL-
mm AcKRS plasmid (Non-opt), the newly constructed pEVOL R3-11 mm AcKRS 
plasmid led to five times increase in production level of sfGFP in the presence of 5 mM 
AcK. Although the results of sfGFP production for cells transformed with plasmids 
pEVOL R3-11 mm AcdKRS and pBAD-sfGFP134TAG were not dramatically higher 
than cells transformed with original pEVOL mm AcdKRS and pBAD-sfGFP134TAG for 
1 mM AcdK, the yield is still improved significantly by about 20%. 
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Figure II-10. Incorporation of 0.2 mM BocK in sfGFP N134TAG using 
WT mm PylRS, R1-7 mm PylRS, R2-23 mm PylRS and R3-11 mm PylRS. 
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Figure II-11. Incorporation of 5 mM AcK in sfGFP N134TAG using WT 
mm AcdKRS and R3-11 mm AcKRS. 
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Figure II-12. Incorporation of 1 mM AcdK in sfGFP N134X using WT 
mm AcdKRS and R3-11 mm AcdKRS. 
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Table II-3. sfGFP N134X[a] protein expression yields for BocK, AcK and AcdK 
ncAAs.   
Synthetase Yield with  
BocK[b] (0.2mM) 
(mg/l) 
Yield with  
AcK[c] (5mM) 
(mg/l) 
Yield with 
AcdK[d] (5mM) 
(mg/l) 
Wild-type synthetase 9.7 4.4 15.5 
R3-11 synthetase 33.8 23.6 18.9 
[a] X=ncAA. [b] synthetase used mm PylRS [c] synthetase used mm AcKRS [d] 
synthetase used mm AcdKRS 
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An important application of the genetic incorporation of AcK is to generate 
acetylated histones for functional investigation of histone acetylation in the regulation of 
chromatin.[114] Therefore, we then tested the improvement in incorporation efficiency of 
the R3-11 mm AcKRS synthetase in incorporating Nϵ -acetyl-L-lysine in histone proteins. 
As explained earlier, histones undergo various post-translational modifications (PTMs) on 
their N-terminal tail which regulate several important cellular processes such as regulation 
of gene expression, cell repair and cell signaling, etc.[22] Acetylation of lysine on the N-
terminal tail of histones is one of the key post-translational modification.[115] This PTM is 
regulated by a set of enzymes known as histone deacetylases (HDACs).[116] Our aim was 
to study the role of one such HDAC, SIRT1[117] to test its deacetylation activity on the 
H3K23AcK site.  
To test this, TAG mutation was introduced in H3 histone at K23 position and the 
WT mm AcKRS and the pEVOL R3-11 mm AcKRS plasmid was coupled with the 
pETDuet H3 K23TAG plasmid. E. coli BL21 cells transformed with these two plasmids 
produced H3 K23AcK with a yield of 9.4 mg/l in LB medium supplemented with 5 mM 
AcK. A control experiment that used the original pEVOL mm AcKRS instead of pEVOL 
R3-11 mm AcKRS only provided a yield of 3.7 mg/l (Figure II-13). As is indicated by the 
results, the R3-11 mutant synthetase significantly improves the amount of acetylated 
histone protein obtained. The acetylated H3 K23 histone was then refolded with H4 
histone to generate a tetramer using H4 histone expressed with SUMO tag for its increased 
production (Figure II-14 showing refolded tetramer with 1:1 H3 K23AcK and H4). This 
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tetramer complex was then subjected to a SIRT1-catalyzed deacetylation assay and then 
probed by a pan anti-acK antibody by Western blot analysis (Figure II-15). 
 
 
 
 
 
 
 
  
Figure II-13. Incorporation of 5 mM AcK in histone H3K23TAG using WT 
mm AcKRS (yield: 3.7 mg/l) and R3-11 mm AcKRS (yield: 9.4 mg/l).  
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Figure II-14. Refolded acetylated histone tetramer of 
H2A, H2B, H3K23AcK and H4 
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Figure II-15. SIRT1 deacetylation assay on WT tetramer 
and acetylated (H3 K23AcK) tetramer. 
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Figure II-16. Comparison of incorporation efficiency of WT PylRS synthetase 
and R3-11 PylRS synthetase for BocK, AcK and AcdK ncAAs. 
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Conclusion 
In summary, as the results indicate (Figure II-16), the mutations identified increase 
the efficiency of the synthetase in incorporation of various ncAAs by a significant extent 
and thus, we have developed a general method to improve ncAA incorporation efficiency 
for the pyrrolysine incorporation system. As indicated by the results, by evolving the N-
terminal region of M. mazei PylRS that directly interacts with tRNAPyl but doesn’t 
participate in the aminoacylation catalysis, we have shown that the three mutations 
identified, R19H, H29R and T122S can significantly improve the incorporation of BocK 
at amber codon. The direct transfer of these three mutations to two other PylRS mutants 
that were previously evolved for the genetic incorporation of AcK and AcdK also 
improved the incorporation efficiency of these two ncAAs, implying that these results can 
be extended to various synthetases to improve incorporation efficiency of several different 
ncAAs with the potential to solve the problem of low yield of expressed protein obtained. 
We hypothesize that this observation could either be a result of increased tRNA synthetase 
solubility or improved tRNA binding to the tRNA synthetase since it has been implicated 
in previous studies[92] that the role of N-terminal domain of archaeal PylRS is responsible 
for binding tRNA. Given the increasing adoption of the pyrrolysine system for basic and 
advanced research, we anticipate broad application of this current method reported by us. 
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CHAPTER III 
GENETICALLY ENCODING HISTIDINE MIMETICS IN PROTEINS USING C-
TERMINAL DOMAIN ENGINEERED PYRROLYSYL SYNTHETASE * 
 
Introduction 
Among the 20 canonical amino acids, histidine is unique in many ways. It is the 
only amino acid with an aromatic but hydrophilic side chain. As illustrated in Figure III-
1, the imidazole side chain can attain two possible neutral forms, in which either of the 
two nitrogen atoms can serve as a hydrogen bond donor or a hydrogen bond acceptor. 
When protonated, the positive charge can oscillate between the two nitrogen atoms for 
initiating favorable charge-charge/dipole interactions in proteins. Due to this unique 
feature histidine has been found in many catalytic charge relay systems in enzymes, 
coordinating charge or proton transfer during catalysis, most commonly observed in 
catalytic triads and catalytic diads in proteases and other hydrolytic enzymes.[118, 119]  
  
                                               
* Reprinted (adapted) with permission from “Probing the Catalytic Charge-Relay System in Alanine 
Racemase with Genetically Encoded Histidine Mimetics.” by V. Sharma, Y.-S. Wang, W. R. Liu, ACS 
Chemical Biology, (2016), 11, 3305-3309. Copyright © 2016 American Chemical Society. 
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Figure III-1. Neutral and charged states of histidine in proteins.  
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To probe the role of histidine in enzymatic reactions, it is usually mutated to 
another residue such as alanine, asparagine or phenylalanine. Although useful for the 
investigation of histidine functions, none of these amino acids can accurately imitate the 
unique characteristics of histidine. Genetic incorporation of structurally similar histidine 
analogs can prove to be a very effective tool in studying biological roles of histidine 
residues in enzymes by fine tuning hydrogen bonding potentials of the histidine side chain. 
As demonstrated by Hsieh et al. (1979), to ascertain the role of a histidine residue in a 
hydrogen-bonding network in an enzyme, substitution of this residue by histidine 
derivatives so as to deprive the availability of proton on pyrrole (-NH) nitrogen or to block 
the proton acceptor site of pyridine (-N) nitrogen of histidine residue can greatly help in 
determining its function as a proton donor/acceptor or a general acid-base in the 
enzyme.[120] Besides genetic incorporation of histidine mimetics, techniques such as native 
chemical ligation (NCL)[32, 33, 96] or the use of auxotrophic bacterial strains[121, 122] can also 
be utilized for studying a system involving histidine mimetics. However, limitations such 
as the modifications possible[34] and the length of the peptide[47] that can be synthesized 
via NCL, toxicity of noncanonical amino acid (ncAA) being incorporated in cellular 
system and undesirable misincorporation via the use of auxotrophic strains[97] render these 
techniques inadequate for studying complex enzymatic systems, consequently directing 
the use of genetic incorporation of ncAAs as the preferred technique. In this chapter, we 
show we show that two close mimetics of histidine, 3-methyl-histidine (Mh) and thiazole 
alanine (Ta), can be genetically encoded using engineered pyrrolysine incorporation 
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machinery. We further show its application in probing the mechanism of action of an 
enzyme known as alanine racemase.  
 
 
 
 
 
 
 
  
Figure III-2. Histidine derivatives 3-methyl 
histidine (Mh) and thiazole alanine (Ta) used in the 
study.  
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Experimental Details 
General Experimental Procedure 
E. coli Top10 were co-transformed with a pEVOL-pylT-PylRS(N346A/C348A) 
plasmid containing tRNACUA
Pyl
 and two copies of PylRS N346A/C348A mutant (previously 
reported)[90] and a pBAD plasmid containing the gene encoding alanine racemase (AlaR). 
QuickChange® mutagenesis was performed to obtain three different alanine racemase 
mutants with the following mutations:  H166TAG, H200TAG and H127TAG. The 
transformed cells were grown overnight at 37°C, 250 rpm, in auto-induction media[123] 
and supplemented with 2 mM of the ncAA to obtain six corresponding mutant enzymes. 
To study the activity of the alanine racemase enzyme and its derivatives, the 
enzyme kinetic activity assay was employed. The assay consisted of coupled reactions 
between conversion of D-alanine to L-alanine and subsequent reaction of L-alanine with 
L-alanine dehydrogenase to form NADH which is detectable by its absorbance at 340 nm. 
All the reactions were carried out at room temperature in a buffer containing 50 µM PLP 
(Pyridoxal Phosphate), 0.1 M KCl, 0.1 M CHES (N-Cyclohexyl-2-aminoethanesulfonic 
acid) Buffer (pH 9.0), 10 mM NAD+, and 0.1 – 10 mM D-alanine and 2 units/mL of L-
alanine dehydrogenase.[124] The extinction coefficient of NADH used for calculations was 
6220 M-1 cm-1. The enzyme concentrations were 0.11 nM for WT, 0.09 µM for H166Ta, 
0.16 µM for H166Mh, 0.17 µM for H200Ta, 0.12 µM for H200Mh, 0.17 µM for H127Ta 
and 0.37 µM for H127Mh. The kinetic parameters kcat and kcat/KM values were then 
calculated. 
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Primer List 
AlaR- KpnI-F, 5’- GCC GGT GGT ACC TCA GTG GTG GTG -3’ 
AlaR- NcoI-R, 5’- GCC TGG CCA TGG ATG AAC GAC TTT CAT C -3’ 
Del-pBAD-alaR-F, 5’- ATG AAC GAC TTT CAT CGC GAT ACG TGG GCG -3’ 
Del-pBAD-alaR-R, 5’- GGT TAA TTC CTC CTG TTA GCC CAA AAA ACG GG -3’ 
His 125A-R, 5’ - CGC AAT AGG AAA AGG GCC -3’ 
His 125-TAG-F, 5’ - TTC CAT TTG AAA ATG GAC ACC -3’ 
His 125-TAG-R, 5’ - CTA AAT AGG AAA AGG GCC GCT -3’ 
His 127A-R, 5’ - CGC GAA ATG AAT AGG AAA AGG GCC GCT G -3’ 
His 127-QC-F, 5’- TTG AAA ATG GAC ACC GGC ATG GGA CG -3’ 
His 127-QC-R, 5’- CTA GAA ATG AAT AGG AAA AGG GCC GCT G -3’ 
H166A-QC-R, 5’ - CGC CGT GTA CAC CCC TTC AAG CAC AA -3’ 
H166F-QC-R, 5’ - AAA CGT GTA CAC CCC TTC AAG CAC AA -3’ 
His 166-QC-F, 5’- TTT GCG ACT GCG GAT GAG GTG AAC AC -3’ 
His 166-QC-R, 5’- CTA CGT GTA CAC CCC TTC AAG CAC AA -3’ 
His 200A-R, 5’ - CGC GAC GAG CGG CGG GCG CG -3’ 
His 200-QC-F, 5’- TGC GCC AAC AGC GCA GCG TCG CTC CG -3’ 
His 200-QC-R, 5’- CTA GAC GAG CGG CGG GCG CGA CGG CAG -3’ 
His 200A-R, 5’ - CGC GAC GAG CGG CGG GCG CG -3’ 
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Plasmid Construction 
For construction of the plasmid for expression of alanine racemase, the AlaR gene 
was amplified from pET23a-wtAlaR by flanking primers, AlaR- KpnI-F and AlaR- NcoI-
R.  The gene product was digested by the restriction enzymes KpnI and NcoI, purified and 
ligated into pBad vector digested by KpnI and NcoI restriction enzymes to generate 
plasmid pBAD-AlaRwt-His6x as shown in Figure III-3. The NcoI restriction digestion site 
was then removed from the pBAD vector by primers Del-pBAD-alaR-F and Del-pBAD-
alaR-R as listed above. 
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Figure III-3. Map showing pBAD AlaRwt-His6x plasmid.  
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The plasmids (i) pBAD-AlaR H125A-His6x, (ii) pBAD-AlaR H125TAG-His6x, 
(iii) AlaR H127TAG-His6x, (iv) pBAD-AlaR H166A-His6x, (v) AlaR H166F-His6x, (vi) 
AlaR H166TAG-His6x, (vii) pBAD-AlaR H200TAG-His6x and (viii) pBAD-AlaR 
H127A H166A H200A-His6x were all derived from the plasmid pBAD-AlaRwt-His6x by 
introducing mutations by site-directed mutagenesis using the following primers 
respectively: (i) His 125-TAG-F and His 125A-R, (ii) His 125-TAG-F and His 125-TAG-
R, (iii) His 127-QC-F and His 127-QC-R (iv) His 166-QC-F and H166A-QC-R (v) His 
166-QC-F and H166F-QC-R, (vi) His 166-QC-F and His 166-QC-R, (vii) His 200-QC-F 
and His 200-QC-R, (viii) His 127-QC-F and His 127A-R, His 166-QC-F and H166A-QC-
R & His 200-QC-F and His 200A-R. 
All the plasmid sequences were confirmed by DNA sequencing. All 
oligonucleotide primers were purchased from Integrated DNA Technologies, Inc. 
 
DNA Sequences 
 
B. stearothermophilus Alanine Racemase: 
atgaacgactttcatcgcgatacgtgggcggaagtggatttggacgccatttacgacaatgtggcgaatttgcgccgt
ttgctgccggacgacacgcacattatggcggtcgtgaaggcgaacgcctatggacatggggatgtgcaggtggcaaggaca
gcgctcgaagcgggggcctcccgcctggcggttgcctttttggatgaggcgctcgctttaagggaaaaaggaatcgaagcgc
cgattctagttctcggggcttcccgtccagctgatgcggcgctggccgcccagcagcgcattgccctgaccgtgttccgctccg
actggttggaagaagcgtccgccctttacagcggcccttttcctattcatttccatttgaaaatggacaccggcatgggacggctt
ggagtgaaagacgaggaagagacgaaacgaatcgtagcgctgattgagcgccatccgcattttgtgcttgaaggggtgtaca
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cgcattttgcgactgcggatgaggtgaacaccgattatttttcctatcagtatacccgttttttgcacatgctcgaatggctgccgtc
gcgcccgccgctcgtccattgcgccaacagcgcagcgtcgctccgtttccctgaccggacgttcaatatggtccgcttcggcat
tgccatgtatgggcttgccccgtcgcccggcatcaagccgctgctgccgtatccattaaaagaagcattttcgctccatagccgc
ctcgtacacgtcaaaaaactgcaaccaggcgaaaaggtgagctatggtgcgacgtacactgcgcagacggaggagtggatc
gggacgattccgatcggctatgcggacggcgtccgccgcctgcagcactttcatgtccttgttgacggacaaaaggcgccgat
tgtcggccgcatttgcatggaccagtgcatgatccgcctgcctggtccgctgccggtcggcacgaaggtgacactgattggtc
gccaaggggacgaggtaatttccattgatgatgtcgctcgccatttggaaacgatcaactacgaagtgccttgcacgatcagtta
tcgagtgccccgtatttttttccgccataagcgtataatggaagtgagaaacgccattggccgcggggaaagcagtgcacacca
ccaccaccaccactga 
     H127 
     H166 
     H200 
 
sfGFP S2TAG: 
atggttagcaaaggtgaagaactgtttaccggcgttgtgccgattctggtggaactggatggtgatgtgaatggccataaatttag
cgttcgtggcgaaggcgaaggtgatgcgaccaacggtaaactgaccctgaaatttatttgcaccaccggtaaactgccggttcc
gtggccgaccctggtgaccaccctgacctatggcgttcagtgctttagccgctatccggatcatatgaaacgccatgatttcttta
aaagcgcgatgccggaaggctatgtgcaggaacgtaccattagcttcaaagatgatggcacctataaaacccgtgcggaagtt
aaatttgaaggcgataccctggtgaaccgcattgaactgaaaggtattgattttaaagaaaatggcaacattctgggtcataaact
ggaatataatttcaacagccataatgtgtatattaccgccgataaacagaaaaatggcatcaaagcgaactttaaaatccgtcaca
acgtggaagatggtagcgtgcagctggcggatcattatcagcagaataccccgattggtgatggcccggtgctgctgccggat
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aatcattatctgagcacccagagcgttctgagcaaagatccgaatgaaaaacgtgatcatatggtgctgctggaatttgctaccg
ccgcgggcattacccacggtatggatgaactgtataaaggcagccaccatcatcatcaccattaa 
 
Protein Sequences 
 
B. stearothermophilus Alanine Racemase: 
MNDFHRDTWA EVDLDAIYDN VANLRRLLPD DTHIMAVVKA NAYGHGDVQV 
ARTALEAGAS RLAVAFLDEA LALREKGIEA PILVLGASRP ADAALAAQQR 
IALTVFRSDW LEEASALYSG PFPIHFHLKM DTGMGRLGVK DEEETKRIVA 
LIERHPHFVL EGVYTHFATA DEVNTDYFSY QYTRFLHMLE WLPSRPPLVH 
CANSAASLRF PDRTFNMVRF GIAMYGLAPS PGIKPLLPYP LKEAFSLHSR 
LVHVKKLQPG EKVSYGATYT AQTEEWIGTI       PIGYADGVRR LQHFHVLVDG 
QKAPIVGRIC MDQCMIRLPG PLPVGTKVTL IGRQGDEVIS IDDVARHLET 
INYEVPCTIS YRVPRIFFRH KRIMEVRNAI GRGESSAHHH HHH 
 
sfGFP S2X: 
MVXKGEELFT GVVPILVELD GDVNGHKFSV RGEGEGDATN GKLTLKFICT 
TGKLPVPWPT LVTTLTYGVQ CFSRYPDHMK RHDFFKSAMP EGYVQERTIS 
FKDDGTYKTR AEVKFEGDTL VNRIELKGID FKENGNILGH KLEYNFNSHN 
VYITADKQKN GIKANFKIRH NVEDGSVQLA DHYQQNTPIG DGPVLLPDNH 
YLSTQSVLSK DPNEKRDHMV LLEFATAAGI THGMDELYKG SHHHHHH 
X represents ncAA 
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Expression and Purification of sfGFP-S2X 
For expression of sfGFP S2X, where X is Mh or Ta, the following expression and 
purification protocol was followed. E. coli Top10 cells were co-transformed with a 
pEVOL-pylT-PylRS(N346A/C348A) plasmid containing tRNACUA
Pyl
 and two copies of 
PylRS N346A/C348A mutant and pBAD sfGFP S2TAG plasmid. The transformed cells 
were grown overnight at 37°C, 250 rpm, in minimal media and supplemented with 2 mM 
of the ncAA. The culture was inoculated in the auto-induction media (50 mL) containing 
100 mg/mL ampicillin and 34 mg/mL chloramphenicol and Mh or Ta were added to final 
concentration of 2 mM after growing the cells in the media for 30 min. The protein 
expression was induced when the culture reached OD600 of 0.5 by adding arabinose to a 
final concentration of 0.2 %. After 24 h expression, the cells were harvested (4k 20 min, 
4°C), washed, and fully resuspended with a lysis buffer (300 mM NaCl, 50 mM NaH2PO4, 
10 mM imidazole, pH 7.5). The sonication of cells underwent under ice/water incubation 
for 3 times (2 min each time with an interval of 5 min). Then the cell lysate was centrifuged 
(10k 40 min, 4°C), and the supernatant was collected. 1 mL Ni SepharoseTM 6 Fast Flow 
column (GE Healthcare) was added to the supernatant and incubated for 1 h at 4°C. The 
mixture was loaded to a column and the flow-through was removed. 15 mL of wash buffer 
(300 mM NaCl, 50 mM NaH2PO4, 20 mM imidazole, pH 7.5) was used to wash the 
protein-bound resin in three batches followed by 5 mL of elution buffer (300 mM NaCl, 
50 mM NaH2PO4, 250 mM imidazole, pH 7.5) to elute the target protein. All the eluted 
fractions were collected and concentrated by Amicon Ultra-15 Centrifugal Filter Device 
(10k MWCO, Millipore), and dialyzed in 20 mM phosphate pH 8.5 buffer 3 times. FPLC 
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Q-Sepharose anion exchange column was used to further purify the sfGFP S2X protein. 
The elution samples were collected and again concentrated by Amicon Ultra-15 
Centrifugal Filter Device (10k MWCO, Millipore). The protein expressions were analyzed 
on 12% SDS-PAGE and quantified using BCA Assay. 
 
Expression and Purification of alaR mutants 
For expression of alanine racemase mutant proteins, E. coli Top10 cells were co-
transformed with a pEVOL-pylT-PylRS(N346A/C348A) plasmid containing tRNACUA
Pyl
 
and two copies of PylRS N346A/C348A mutant[90] and  corresponding pBAD-alaRHxxx-
His6x plasmid with TAG mutation at the required histidine position. The transformed cells 
were grown overnight at 37°C, 250 rpm, in auto-induction media (with tyrosine, cysteine, 
histidine, phenylalanine and tryptophan left out of the media)[123] and supplemented with 
2 mM of the ncAA. The culture was inoculated in the auto-induction media (50 mL) 
containing 100 mg/mL ampicillin and 34 mg/mL chloramphenicol and Mh or Ta were 
added to final concentration of 2 mM after growing the cells in the media for 30 min. The 
protein expression was induced when the culture reached OD600 of 0.5 by adding arabinose 
to a final concentration of 0.2 %. After 24 h induction, cells were harvested, resuspended 
in lysis buffer (50 mM NaH2PO4, 300 mM NaCl, 10 mM imidazole, pH 8.0) supplemented 
with 20 µM pyridoxal-5'-phosphate (PLP) and sonicated. The cell lysate was clarified by 
centrifugation (30 min, 11,000 g, 4ºC). The supernatant was injected into a 30 mL Ni2+-
NTA column (Qiagen) and washed with 60 to 90 mL lysis buffer. Protein was finally 
eluted out by running an imidazole gradient from 10 mM to 250 mM in lysis buffer. Pure 
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fractions were collected and concentrated. The eluted protein was dialyzed against 1X 
PBS buffer with 20 µM PLP concentrated using an Amicon Ultra-15 Centrifugal Filter 
(10,000 MWCO). The purified proteins were analyzed by 12% SDS-PAGE. AlaRHxxx-
His6X mutant proteins incorporated with Mh and Ta were expressed and purified with the 
yields as shown in Figure III-4. 
 
 
 
 
 
 
 
  
Figure III-4. Expression of alanine racemase mutants supplied with 
2mM ncAA.  
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Kinetic Assay for studying enzymatic activity 
 
 
 
The kinetic assay employed to study the enzymatic activity of WT alanine 
racemase and the mutant enzymes consisted of coupled reactions between conversion of 
D-alanine to L-alanine and subsequent reaction of L-alanine with L-alanine dehydrogenase 
to form NADH which is detectable by its absorbance at 340 nm. All the reactions were 
carried out at room temperature in a buffer containing 50 µM PLP (Pyridoxal Phosphate), 
0.1 M KCl, 0.1 M CHES (N-Cyclohexyl-2-aminoethanesulfonic acid) Buffer (pH 9.0), 10 
mM NAD+, and 0.1 – 10 mM D-alanine and 2 units/mL of L-alanine dehydrogenase.[124]  
The extinction coefficient of NADH used for calculations was 6220 M-1 cm-1. The enzyme 
concentrations were 0.11 nM for WT, 0.09 µM for H166-Ta, 0.16 µM for H166-Mh, 0.17 
µM for H200-Ta, 0.12 µM for H200-Mh, 0.17 µM for H127-Ta and 0.37 µM for H127-
Mh. All the measurements were made at 340 nm on UV-1800 UV-Spectrophotometer, 
Shimadzu®.  
 
Circular Dichroism Analysis 
All the mutant protein samples were further purified on FPLC (Bio-Rad, NGCTM 
Chromatography System) and dialyzed in 20 mM borate buffer (pH 9.1) to prepare their 
samples for measurement. Circular dichroism (CD) measurements were made on AVIV-
62DS spectrometer using quartz cuvette of 1 mM path-length. CD spectra was recorded 
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at 25°C in 20 mM borate buffer (pH 9.1) purified by filtration before use. Data was 
collected from 190 nm to 280 nm in increments of 1 nm with averaging time of 10s. 
Concentrations of all protein samples were normalized to 0.022 mg/mL for helicity 
calculations. Fraction helicity (fh) was calculated using the ellipticity data at 222 nm 
obtained according to the method described by Rohl et al. (1997).[125] The following 
formula was used for the calculations: fh= 
𝜃222 nm (obs)– 𝜃222 nm (coil)
𝜃222 nm (α- helix) -θ222 nm (coil)
; = 
𝜃222− 𝜃C
𝜃H− 𝜃C
. In this 
formula, 𝜃 = mean residue ellipticity, 𝜃C = 2220 – 53 * T (in °C) = 2220 – 53 * 25= 895 
deg cm2 d mol-1, 𝜃H = (-44000+ 250 * T (in °C) [1 −
3
𝑁res
] = (-44000 + 250 * 25) (1-
3
393
) = 
-37461.8 deg cm2 d mol-1 and Nres = Number of residues. The calculated % helicity of 
mutant samples as compared to wild-type alanine racemase (22.7 %) are listed in the Table 
II-1 below:  
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Table III-1. Calculated % helicity of alanine 
racemase and its mutants.  
Enzyme % Helicity 
WT  22.7 
H166Mh 22.9 
H166Ta 20.4 
H200Mh 21.6 
H200Ta 19.9 
H127Mh 21.7 
H127Ta 20.7 
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Results and Discussion 
In order to create a mutagenic system that genetically incorporates ncAAs that 
closely mimic histidine for fine tuning of histidine-involved hydrogen bonding 
interactions, we referred to the engineering of the pyrrolysine incorporation 
machinery.[126] We set our sights on the incorporation of histidine analogs such as 3-
methyl-histidine (Mh) and thiazole alanine (Ta), as both are close histidine mimetics. We 
have previously shown that a rationally designed pyrrolysyl-tRNA synthetase variant with 
the mutations  N346A/C348A (PylRS(N346A/C348A)) can recognize a large number of 
phenylalanine derivatives and, together with its cognate tRNACUA
Pyl
, mediate their 
incorporation into proteins at amber (TAG) codons in Escherichia coli and mammalian 
cells.[100, 101] Given the similarity between some phenylalanine derivatives and histidine 
analogs we predicted that this same enzyme can also recognize these ncAAs and direct 
their incorporation into proteins at amber codons. To test this proposition, E. coli BL21 
cells coding PylRS(N346A/C348A), tRNACUA
Pyl
, and superfolder green fluorescent protein 
(sfGFP) with an amber mutation at the S2 position were grown in minimal media 
supplemented with 5 mM Mh or Ta. For both ncAAs, their presence in the growth media 
promoted the suppression of the amber mutation in sfGFP and the subsequent full-length 
protein expression. Without providing a ncAA, no full-length sfGFP was expressed 
(Figure III-5).  
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Figure III-5. The selective incorporation of Mh and Ta into sfGFP at 
its S2 position. 
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The electrospray ionization mass spectrometry (ESI-MS) analysis of the purified 
proteins detected molecular weights of 27,732 Da for the Mh-incorporated protein and 
27,735 Da for the Ta-incorporated protein that agree well with the theoretical molecular 
weights (27,733 and 27,736 Da, respectively), confirming the selective incorporation of 
these two ncAAs and the high fidelity of the incorporation system (Figure III-6 and Figure 
III-7). Mh has also been genetically encoded using an alternative system.[127] 
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Figure III-6. ESI-MS analysis of sfGFP S2Mh (theoretical molecular weight: 
27, 733 Da) 
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Figure III-7. ESI-MS analysis of sfGFP S2Ta (theoretical molecular weight: 
27, 736 Da) 
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We envisioned that the incorporation of both Mh and Ta can be applied to probe 
fundamental roles of histidine in charge-relay systems of enzymes. Instead of probing well 
studied catalytic triads and diads, we chose to investigate histidine functions in a 
potentially extended charge-relay system in alanine racemase (EC 5.1.1.1). Alanine 
racemase has become a promising drug target since the discovery of its key role in the 
formation of peptidoglycan in bacterial cell walls.[128-132] Mechanistic illustration of this 
enzyme may facilitate the identification of inhibitors[112, 133-138] that can serve as novel 
antibiotics. This Pyridoxal 5’-Phosphate (PLP)-dependent enzyme catalyzes the 
interconversion of L-alanine to D-alanine.[139-141] Although it is one of the most well studied 
enzymes, information on several aspects of its mechanism remains elusive. It is known 
that alanine racemase employs a two-base catalytic mechanism in which K39 and Y265 
residues act as general acid/base catalysts[142] (Figure III-8).  
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Figure III-8. The catalytic mechanism of alanine racemase.  
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In the racemization reaction from D-alanine to L-alanine, D-alanine first reacts with 
PLP to form an external aldimine. K39 then abstracts the α proton from this external 
aldimine to generate a quinonoid intermediate that receives a proton from Y265 to form a 
second external aldimine. L-alanine is then released from this external aldimine as the final 
product. The whole catalytic process is fully reversible. pH profile studies have indicated 
that the phenolic hydroxide of Y265 has a pKa value around 7.1-7.4, contributing to a very 
high catalytic rate of wild-type alanine racemase with a kcat/KM of 1.6 (0.2)×10
6 M-1s-1 
.[124] We predicted the existence of an extended charge-relay system and hydrogen bonding 
network involving residues E161, H127, H200, R219, H166, and Y265 in alanine 
racemase that are potentially involved in bringing down the pKa of the Y265 side chain 
hence affecting the catalytic activity of the enzyme (Figure III-9). E161 is solvent exposed 
as determined by the active site structure of alanine racemase from Bacillus 
stearothermophilus (PDB: 1SFT).[143]  
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Figure III-9. The active site structure of B. stearothermophilus alanine 
racemase (PDB:1SFT) showing predicted charge relay system.  
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There are three histidine residues involved in this proposed charge-relay system. 
It has been shown that H166 coordinates the activation of Y265 by R219.[124] Although 
H127 and H200 are distal from Y265, they potentially serve critical roles in the activation 
of Y265 through this charge-relay system with the extended hydrogen bonding network. 
To test this proposition and directly observe how hydrogen bonding interactions contribute 
to the final activation of Y265, we decided to substitute these two residues in addition to 
H166 with either Mh or Ta using our established system for the incorporation of these two 
ncAAs. In total, six alanine racemase mutants containing these ncAAs were expressed and 
purified to homogeneity. Circular dichroism analysis of purified proteins indicates that 
they all fold like the wild-type enzyme (Figure III-10). This is an expected observation 
given that both Mh and Ta are highly analogous to histidine with Ta being almost spatially 
identical to histidine. Two mutants H166Ta and H166Mh were also characterized by the 
mass spectrometry analysis to confirm the incorporation of Ta and Mh (Figure III-11 and 
Figure III-12). Catalytic activity of these mutant enzymes along with wild-type alanine 
racemase enzyme was characterized according to the methods of Sun et al.[124] and the 
determined values are presented in Table III-2.   
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Figure III-10.  Circular dichroism spectra of wild-type alanine 
racemase and its six mutants.  
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Figure III-11. ESI-MS of alanine racemase H166-Mh mutant. Theoretical molecular 
weight is 44,601 Da which corresponds well with the major peak observed in the 
spectra of 44,602 Da. 
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Figure III-12. MS/MS analysis of alanine racemase H166-Ta mutant. The 
b1 ion indicates presence of thiazole alanine at the 166 position of the 
alanine racemase mutant sample. 
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Table III-2. Catalytic parameters of wild-type alanine racemase and its mutants 
 
Enzyme kcat (s-1) Rel. kcat KM 
(mM) 
kcat/KM  
(M-1s-1) 
Rel. kcat/KM 
wild type 3.5 (0.1) × 103 1 2.2 1.6 (0.2) × 106 1 
H166Ta 1.7 (0.1) × 101 0.005 0.5 3.3 (0.2) × 104 0.02 
H166Mh 8.4 (0.3) × 100 0.002 0.5 1.8 (0.2) × 104 0.01 
H200Ta 1.2 (0.5) × 101 0.003 1.6 7.3(0.8) × 103 0.005 
H200Mh 5.2 (0.2) × 100 0.002 1.6 3.2 (0.4) × 103 0.002 
H127Ta 1.2 (0.4) × 101 0.003 1.2 1.0 (0.1) × 104 0.006 
H127Mh 2.2 (0.1) × 101 0.006 1.8 1.2 (0.2) × 104 0.007 
H125Ta 4.1 (0.2) × 103 0.8 4.7 8.7 (0.4) × 105 0.5 
H125A 4.4 (0.2) × 102 0.08 0.5 8.2 (0.4) × 105 0.5 
H166A 3.5 (0.2) × 100 0.001 1.6 2.2 (0.3) × 103 0.001 
H166F 3.9 (0.1) × 100 0.001 3.9 1.0 (0.1) × 103 0.0006 
H127A/H166A/H200A 2.8 (0.4) × 10-1 0.00008 0.8 3.6(0.5) × 102 0.0002 
 110 
 
Substituting any of the three histidines predicted to be involved in the charge-relay 
system with either Mh or Ta has a dramatic effect on the enzyme’s catalytic activity. All 
of the generated mutants displayed diminished activities with more than 100-fold decrease 
in kcat in comparison to their wild-type counterpart. Given the established role of H166 in 
the direct activation of Y265, low activities of mutants H166Mh and H166Ta are expected. 
However, H127 and H200 are distal from Y265 with no direct interaction possible 
between the tyrosine and histidine residues. Both of these residues are more than 10Å 
away from the catalytic site and more than 15Å away from the phenolic hydroxide group 
on the side chain of Y265. Therefore, such a drastic decrease in activity observed for H127 
and H200 mutants strongly suggests that the side chains on these histidine residues are 
involved in activation of Y265 residue. Although the methyl group of Mh potentially 
disrupts the orientation of vicinal amino acid side chains of H127 and H200 when these 
two sites are substituted with Mh, Ta is spatially similar to histidine and therefore its 
substitution at H127 and H200 is expected to have minimal impact on the local protein 
structure around H127 and H200 residues. Unlike histidine whose two side chain nitrogen 
atoms can both serve as donor and acceptor roles in hydrogen bonding interactions, the 
low pKa (~2) of the thiazole side chain of Ta dictates that both nitrogen and sulfur in the 
Ta side chain can only serve as hydrogen bond acceptors. This implies that the proton 
transfer chain as suggested by us, where the phenolic group of Y265 accepts a proton from 
the side chain of H166 which in turn accepts a proton from R219 and then extending this 
charge relay system, the side chain of H200 donates a proton to R219 while accepting a 
proton from the side chain of H127, would be interrupted on changing the proton donating 
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ability of all the histidine residues involved. This is illustrated by the diminished activity 
of enzyme observed by replacing H127, H200, and H166 with Ta, suggesting that the 
hydrogen bonding network in the predicted extended charge-relay system is disrupted and 
subsequently prohibits the direct activation of Y265 by this charge-relay system. All the 
mutant enzymes retain similar basal level activities possibly due to the access of Y265 to 
water molecule which acts as a substitute to the charge-relay system in activating the Y265 
residue. 
Contrary to their dramatic decreased kcat values in comparison to the wild-type 
enzyme, H200Ta, H200Mh, H127Ta, and H127Mh have KM values almost identical to 
that of the wild-type enzyme. This is expected since both H200 and H127 are distal to the 
active site and their replacement with Ta and Mh minimally affects the active site 
structure. However, both H166Ta and H166Mh have KM values 4-fold lower than that of 
the wild-type enzyme. In comparison to histidine, both Ta and Mh are more hydrophobic. 
Their replacement of H166 may create a more hydrophobic active site environment that 
favors the substrate reaction with the bound PLP. For comparison purpose, we also 
expressed and determined catalytic activities of H166A and H166F mutants. Although 
both mutants show kcat values not much lower than H166Ta and H166Mh, they have much 
higher KM values, leading to overall kcat/KM values more than 10-fold lower than those of 
H166Ta and H166Mh. This observation may be because Ta and Mh mimic histidine better 
than ala and phe and therefore minimally disrupt the substrate binding when replacing 
H166. When H166, H200, and H127 are all replaced with Ala, the afforded mutant has a 
very low activity as expected. We also mutated H125, a histidine not part of the potential 
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charge relay system, to Ta and determined the activity of the afforded H125Ta mutant to 
serve as a control. As expected we observe no significant change in kcat by introducing this 
mutation, the result indicates that H125Ta is solvent exposed and does not play any 
significant role in the activity of the enzyme as this surface-exposed residue is far away 
from the active site of the enzyme. A similar mutation at H125 to alanine also caused 
insignificant change to the catalytic activity of the enzyme. CD spectra of the wild-type 
enzyme and two H125 mutants are very similar, indicating no significant structural 
differences between them.  
 
Conclusion 
In summary, we have shown that the two close mimetics of histidine, Mh and Ta, 
can be genetically incorporated into proteins at amber codons using an engineered 
pyrrolysine incorporation machinery. Given their spatial resemblance and contrasting 
hydrogen bonding characteristics, replacing a histidine in a protein with Mh or Ta is 
expected to introduce minimal impact on the protein secondary structure, allowing for the 
fine tuning of the hydrogen bonding interactions critical in their enzymatic activity. By 
tweaking the hydrogen bonding interactions in a potentially extended charge-relay system 
by replacement of histidine residues involved in this system with Mh and Ta, we have 
demonstrated the possibility that all the histidine residues in this charge-relay system, 
H166, H200 and H127, coordinate the activation of the Y265 residue at the active site for 
catalysis, therefore suggesting the existence of this extended charge-relay system. The 
reported method can be easily adapted to study functional roles of histidine in many 
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proteins and enzymes and is expected to have profound impact in the biochemistry 
research area. One drawback of the reported method is the disruption of the hydrogen 
bonding system. An alternative solution is to the genetically incorporate fluorohistidines 
that allows fine-tuning histidine pKa while maintaining all the hydrogen bonding potential.  
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CHAPTER IV 
CONCLUDING REMARKS AND FUTURE OUTLOOK 
 
 
In this dissertation, we accomplished improvement in an existing genetic 
incorporation tool, pyrrolysyl-tRNA/synthetase, which has been widely used over the past 
several years in incorporating several different ncAAs. This was achieved by evolving the 
N-terminal domain of M. mazei pyrrolysyl-tRNA synthetase that directly interacts with 
tRNAPyl, and a mutant clone that displayed improved amber suppression efficiency for the 
genetic incorporation of Nϵ-(tert-butoxycarbonyl)-L-lysine three-fold more than the wild 
type synthetase.  
Direct transfer of mutations R19H/H29R/T122S identified in this clone to two 
other PylRS mutants that were previously evolved for the genetic incorporation of Nϵ-
acetyl-L-lysine and Nϵ-(4-azidobenzoxycarbonyl)-δ,ϵ-dehydrolysine also improved the 
incorporation efficacy of these two noncanonical amino acids. Since the three identified 
mutations are in the N-terminal domain that is separated from the catalytic domain for 
charging tRNAPyl with a noncanonical amino acid, they can be potentially introduced to 
all other PylRS mutants for improving incorporation efficiency of their corresponding 
noncanonical amino acids, representing a general strategy to optimize pyrrolysine system-
based noncanonical amino acid mutagenesis.  
We also show in this dissertation, a method to incorporate histidine derivatives in 
proteins. Histidine, a unique amino acid with an imidazole side chain in which both the 
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nitrogen atoms can serve as a proton donor and proton acceptor in hydrogen bonding 
interactions, plays an important role in activity of several enzymes. Traditional methods 
are not ideal to probe the functional role of these histidines which are part of hydrogen 
bonding networks as fine-tuning the hydrogen bonding potential of the imidazole side 
chain is required for such a study but is infeasible due to limitations of the conventional 
mutagenesis methods.  
Here, we showed incorporation technique for genetically encoding two histidine 
mimetics, 3-methyl-histidine and thiazole alanine, using engineered pyrrolysyl-
tRNA/synthetase incorporation machinery. Our results verified the existence of an 
extended charge-relay system in alanine racemase with the alanine racemase mutants 
installed with 3-methyl-histidine or thiazole alanine at the predicted key histidine sites 
showing a dramatic loss in the enzyme’s catalytic efficiency. This hinted at the role of this 
predicted charge-relay system in activating the Y265 residue present at the active site of 
the enzyme. Thus, this method can potentially serve as a useful tool in discerning function 
of key histidine residues, part of catalytic diads/triads of several enzymes and provide 
crucial information in enzyme mechanism which can be useful for design and 
development of inhibitors for these enzymes. 
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